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ABSTRACT 
Attention deficit hyperactivity disorder (ADHD) is characterized by developmentally 
inappropriate levels of inattention, hyperactivity, and impulsivity, and is the most 
common neurodevelopmental disorder of childhood. This highly prevalent disorder is 
estimated to affect about 5% of school-age children worldwide, with a substantial 
degree of persistence over time. Although the specific cause of ADHD is still largely 
unknown, despite a long history of research, it is believed to involve multiple genetic 
and environmental factors. ADHD is also associated with considerable comorbidities 
and functional impairments, which place a substantial burden on affected individuals, 
their families and society. Stimulant medication is considered as one of the most 
important treatments for ADHD, but the increased use over the years has also raised 
numerous public concerns. Therefore, the general aim of this thesis was to investigate 
how genetic and environmental factors contribute to the development of ADHD, as 
well as to investigate the consequences of ADHD and potential effects of ADHD 
medication. 
 
Study I explored the relative contribution of genetic and environmental influences of 
ADHD from childhood through early adulthood. The study found that the shared view 
of self- and informant-rated ADHD is highly heritable in childhood, adolescence, and 
early adulthood. It also found evidence of both stable and dynamic genetic influences 
on ADHD over the course of the development. 
 
Study II examined the association between young maternal age at childbearing and 
subsequent risk for ADHD in offspring, using a genetically-informative design. The 
study found that maternal age at first birth, not maternal age at the current birth, 
predicted offspring ADHD. Thus, all offspring born to teenage mothers were at 
increased risk of ADHD. The association was mainly explained by passive gene-
environment correlations. That is, genetic factors transmitted from mothers to children 
contribute to both mothers’ age at childbearing and ADHD in offspring. 
 
Study III investigated how the two symptom dimensions of ADHD (hyperactivity-
impulsivity and inattention) are associated with early-onset substance use. The study 
found that that hyperactivity-impulsivity, but not inattention, independently predicted 
early-onset tobacco use, even after controlling for conduct problems. Twin analyses 
showed that the association between hyperactivity-impulsivity and early-onset 
substance use were mainly influenced by genetic factors. 
 
Study IV estimated the association between ADHD and the risk of serious transport 
accidents, and explored the extent to which ADHD medication influenced this risk 
among ADHD patients. The study found that ADHD patients were at increased risk for 
serious transport accidents, and that ADHD medication was associated with a 
significant reduction of accidents, among males patients, even when using within-
individual analyses to control for confounding. 
  
Study V explored whether stimulant ADHD medication is associated with risk for long-
term substance abuse. The study found no indication of increased substance abuse at 
follow-up. Rather, the results suggested there was a decrease in substance abuse for up 
to four years after taking ADHD medications, and that patients who took ADHD 
medication for longer durations had lower rates of substance abuse. 
 
In conclusion, ADHD is a prevalent, persistent and impairing disorder. Genetic factors 
play an important role in the development of the disorder from childhood to adulthood. 
ADHD predicts poor developmental and health outcomes, and ADHD medications 
appear to be useful in reducing some serious adverse outcomes, such as transport 
accidents and substance abuse. The findings in this thesis highlight the importance of 
using quasi-experimental designs, including genetically-informative studies, when 
exploring how risk factors and adverse consequences are associated with ADHD. 
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1 INTRODUCTION 
Attention deficit hyperactivity disorder (ADHD) is the most common neuro-
developmental disorder of childhood. This highly prevalent disorder is estimated to 
affect about 5% of school-age children worldwide, and it exhibits a substantial degree 
of persistence over time. ADHD is characterized by developmentally inappropriate 
levels of inattention, hyperactivity, and impulsivity, and is associated with considerable 
comorbidity and impairments. The etiology of ADHD is multifactorial and composed 
of multiple genetic and environmental factors. Because of its high prevalence and its 
associated impairments and adverse outcomes, ADHD is considered a major public 
health problem. Pharmacological treatment, including stimulant medication, plays an 
important role in the management of ADHD. The general aim of this thesis was to 
investigate how genetic and environmental factors contribute to the development of 
ADHD, as well as to investigate the consequences of ADHD and potential effects of 
ADHD medication. 
 
1.1 ADHD 
An early description of ADHD-like problem was made in 1798 by Scottish-born 
physician Sir Alexander Crichton, as “mental restlessness", a mental state that is much 
like the inattention symptom of ADHD today [1]. In 1902, British pediatrician Sir 
George Still described 43 children who had serious problems with sustained attention 
and self-regulation, which is considered to be the beginning of the modern conception 
of ADHD [2]. Since then, researchers and clinicians have been struggling to understand 
this disorder, and the terminology and diagnostic criteria used to describe the condition 
have changed over time. It was described as "minimal brain dysfunction" in the first 
edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-I, 1952), 
and "hyperkinetic reaction of childhood" in the DSM-II (1968). These early terms and 
criteria focused on the motoric hyperactivity and overt impulsivity of patients [3]. The 
DSM-III (1980) represented a paradigm shift, as it began to emphasize inattention as an 
important component of the disorder, and named it "attention-deficit disorder with or 
without hyperactivity"[4]. In 1987 the term was changed to Attention deficit 
hyperactivity disorder (ADHD) in the DSM-III-R [5] and this name continued to be 
used in the DSM-IV (1994) [6] and the new DSM-5 (2013) [7].  
 
1.1.1 Diagnosis 
In the past decade, the major clinical diagnostic systems for ADHD have been included 
in the DSM-IV [6] and the International Classification of Diseases, 10th edition (ICD-
10) [8]. The DSM-IV diagnosis of ADHD is commonly used in North American, and 
the ICD-10 diagnosis is more commonly used in Europe. According to DSM-IV, 
individuals with ADHD show a persistent pattern of inattention and/or hyperactivity-
impulsivity that interferes with their functioning or development (Table 1). Based on 
the prominence of the types of symptoms, three subtypes of ADHD are defined: 
predominantly inattentive, predominantly hyperactive-impulsive, and combined type. 
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Table 1. The DSM-IV diagnostic criteria for ADHD 
A. Either (1) or (2): 
  (1) six (or more) of the following symptoms of inattention have persisted for at least six 
months to a degree that is maladaptive and inconsistent with developmental level: 
   (1) often fails to give close attention to details or makes careless mistakes in school work, 
work or other activities 
   (2) often has difficulty sustaining attention in tasks or play activities 
   (3) often does not seem to listen when spoken to directly 
   (4) often does not follow through on instructions and fails to finish school work, chores, 
or duties in the workplace (not due to oppositional behavior or failure to understand 
instructions) 
   (5) often has difficulty organizing tasks and activities 
   (6) often avoids, dislikes, or is reluctant to engage in tasks that require sustained mental 
effort (such as school work or homework) 
   (7) often loses things necessary for tasks or activities (e.g., toys, school assignments, 
pencils, books or tools) 
   (8) is often easily distracted by extraneous stimuli 
   (9) is often forgetful in daily activities 
  (2) six (or more) of the following symptoms of hyperactivity-impulsivity have persisted for at 
least six months to a degree that is maladaptive and inconsistent with developmental level: 
   (1) often fidgets with hands or feet or squirms in seat 
   (2) often leaves seat in classroom or in other situations in which remaining seated is 
expected 
   (3) often runs about or climbs excessively in situations in which it is inappropriate (in 
adolescents or adults, may be limited to subjective feelings of restlessness) 
   (4) often has difficulty playing or engaging in leisure activities quietly 
   (5) is often "on the go" or often acts as if driven by a motor 
   (6) often talks excessively 
   (7) often blurts out answers before questions have been completed 
   (8) often has difficulty awaiting turn 
   (9) often interrupts or intrudes on others (e.g., butts into conversations or games) 
B. Some hyperactive-impulsive or inattentive symptoms that caused impairment were present before 
age seven years. 
C. Some impairment from the symptoms is present in two or more settings (e.g., at school [or work] 
and at home). 
D. There must be clear evidence of clinically significant impairment in social, academic, or 
occupational functioning. 
E. The symptoms do not occur exclusively during the course of a pervasive developmental disorder, 
schizophrenia or other psychotic disorder and are not better accounted for by another mental 
disorder (e.g., mood disorder, anxiety disorder, dissociative disorder, or a personality disorder). 
The ICD-10 refers to ADHD as "hyperkinetic disorder" (HKD, code: F90). The two 
diagnostic systems include essentially the same list of symptoms, and both take into 
account the symptoms and impairments (Table 2). However, the ICD-10 criteria are 
more restrictive than the DSM-IV diagnosis of ADHD [9], because a diagnosis of HKD 
requires impairments in all three symptom domains, together with stricter exclusion 
criteria. HKD is, therefore, considered a severe form of ADHD, somewhat similar to 
DSM-IV combined subtype. 
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Table 2. The ICD-10 diagnostic criteria for hyperkinetic disorder 
G1 Inattention 
 At least six of the following symptoms of attention have persisted for at least six months, to a 
degree that is maladaptive and inconsistent with the developmental level of the child: 
  (1) often fails to give close attention to details, or makes careless errors in school work, work 
or other activities 
  (2) often fails to sustain attention in tasks or play activities 
  (3) often appears not to listen to what is being said to him or her 
  (4) often does not follow through on instructions and fails to finish school work, chores, or 
duties in the workplace (not due to oppositional behavior or failure to understand instructions) 
  (5) often fails to follow through on instructions or to finish school work, chores, or duties in 
the workplace (not because of oppositional behavior or failure to understand instructions) 
  (6) often avoids or strongly dislikes tasks, such as homework, that require sustained mental 
effort 
  (7) often loses things necessary for certain tasks and activities, such as school assignments, 
pencils, books, toys or tools 
  (8) is often easily distracted by external stimuli 
  (9) is often forgetful in the course of daily activities 
G2 Hyperactivity 
 At least three of the following symptoms of hyperactivity have persisted for at least six months, to 
a degree that is maladaptive and inconsistent with the developmental level of the child: 
  
(1) often fidgets with hands or feet or squirms on seat 
  (2) leaves seat in classroom or in other situations in which remaining seated is expected 
  (3) often runs about or climbs excessively in situations in which it is inappropriate (in 
adolescents or adults, only feelings of restlessness may be present) 
  (4) is often unduly noisy in playing or has difficulty in engaging quietly in leisure activities 
  (5) exhibits a persistent pattern of excessive motor activity that is not substantially modified by 
social context or demands 
G3 Impulsivity 
 At least one of the following symptoms of impulsivity has persisted for at least six months, to a 
degree that is maladaptive and inconsistent with the developmental level of the child: 
  (1) often blurts out answers before questions have been completed 
  (2) often fails to wait in lines or await turns in games or group situations 
  (3) often interrupts or intrudes on others (e.g., butts into others’ conversations or games) 
  (4) often talks excessively without appropriate response to social constraints 
G4 Onset of the disorder is no later than the age of seven years. 
G5 The criteria should be met for more than a single situation, e.g., the combination of inattention and 
hyperactivity should be present both at home and at school, or at both school and another setting 
where children are observed, such as a clinic. (Evidence for cross-situationality will ordinarily 
require information from more than one source; parental reports about classroom behavior, for 
instance, are unlikely to be sufficient.) 
G6 The symptoms in G1 and G3 cause clinically significant distress or impairment in social, 
academic, or occupational functioning. 
G7 The disorder does not meet the criteria for pervasive developmental disorders (F84.-), manic 
episode (F30.-), depressive episode (F32.-), or anxiety disorders (F41.-).  
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While clinical diagnostic classification helps clinicians to identify patients that need 
help, and thereby, to provide treatment and care, there is a long-standing debate 
whether mental disorders are discrete clinical conditions or arbitrary distinctions along 
dimensions of functioning. It has been proposed that most mental disorders (including 
ADHD) may be better represented as quantitative dimensions rather than distinct 
categories [10,11], and this argument is supported by research that demonstrates 
etiological similarities across clinical-diagnosed ADHD and the full range of symptoms 
of inattention, hyperactivity and impulsivity [12,13]. Therefore, ADHD may be viewed 
as the extreme end of a behavioral continuum. In addition to DSM and ICD criteria, 
several rating scales have been developed to provide an in-depth assessment of ADHD 
that complements diagnostic evaluation [14]. Some of the most widely used rating 
scales are: the ADHD Rating Scale, the Conners’ Rating Scales, the Swanson Nolan 
and Pelham Questionnaire, the Vanderbilt ADHD Rating Scales, and the Adult ADHD 
Self-Report Scale. 
 
1.1.2  Prevalence 
ADHD is highly prevalent worldwide, estimated to affect about 5% of school-age 
children [15,16] and about 2-4% of adults [17,18]. Although there is substantial 
geographic variability in the prevalence of ADHD, this variability seems to be 
explained primarily by differences in the methodological characteristics of studies [15]. 
The DSM-IV diagnosis of ADHD produces higher estimates of prevalence than ICD 
diagnosis of HKD, because the ICD criteria are more restrictive. Surveys that estimate 
the prevalence of ADHD based on symptoms alone and do not adequately incorporate 
functional impairment also yield higher estimates. In addition, gender distribution of 
the sample affects the estimates of prevalence, since ADHD is more common in boys 
than girls [19]. The gender difference may be explained by referral bias or under-
diagnosis in girls. Girls usually have more inattentive symptoms and less disruptive 
behaviors than boys, which may lead to lower rates of diagnosis [20]. This gender 
difference is less pronounced in community samples than in clinical samples [21]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Frequency of diagnoses of ADHD (F900) and other psychiatric disorders in Sweden from 2001 
to 2011 (Swedish National Board of Health & Welfare). 
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Rates of ADHD diagnosis have increased over the past years. In the United States, rates 
of ADHD diagnosis increased an average of 3% per year from 1997 to 2006 and an 
average of 5.5% per year from 2003 to 2007. Approximately 9.5% of U.S. children 4-
17 years of age (5.4 million) have been diagnosed with ADHD by 2007, according to 
parent-reports [22], and two thirds of those children received medication for the 
disorder [23]. These rates reflect a marked increase over the last decade and raise 
substantial concerns among the public about the increasing number of ADHD diagnosis 
and medication [24]. A similar trend is also observed in Sweden (Figure 1). However, 
the increased number of diagnoses may be explained by the improved coverage of 
medical registers and the increased recognition of the disorder across time, rather than 
by increased incidences of the disorder itself. Based on a review of prevalence studies 
and research on the diagnostic process, there does not appear to be sufficient evidence 
that that ADHD is systematically over-diagnosed [25]. On the other hand, there are also 
misdiagnoses and underdiagnoses.  
 
1.1.3 Persistence 
ADHD has long been considered as a childhood disorder that did not continue beyond 
adolescence. This idea has been challenged by systematic follow-up studies of children 
with ADHD, which documented a substantial degree of persistence over time [26-28]. 
The prevalence of ADHD in adults is estimated to be about 2-4% [17,18], which means 
that it is one of the most common psychiatric disorders in clinical settings and society at 
large. The degree of persistence depends largely on the definition of ADHD in adults. 
Adults must have childhood-onset, persistent and current symptoms of ADHD to be 
diagnosed with the disorder. DSM-IV-TR [29] added “in partial remission” that can be 
applied to individuals who have some persistent symptoms and continued clinical 
impairment, but no longer fulfill the full criteria. Meta-analysis has shown that 
approximately 15% of children with ADHD continue to meet the full criteria up to 25 
years of age, but when including ADHD in partial remission, the rate of persistence is 
much higher, approximately 65% [28].  
 
Longitudinal studies have shown that inattention symptoms tend to persist across the 
development to a greater extent than symptoms of hyperactivity and impulsivity, which 
indicate the predominant symptom features of childhood and adult ADHD may differ 
[30-32]. Adults with ADHD tend to have impediments in many areas of life, including 
work, daily activities, social and family relationships and psychological and physical 
well-being [33]. The substantial societal burden of adult ADHD highlights the 
importance of increasing our understanding of the disorder and of ways to develop 
better treatment strategies. 
 
Despite increased interest about adult ADHD [34,35], ADHD is still largely under-
diagnosed in adults [36]. Besides the low levels of social and clinical recognition of 
adult ADHD, the lack of developmentally appropriate diagnostic criteria for ADHD in 
adults has made diagnoses difficult. The DSM-5 makes a special effort to address 
adults affected by ADHD to ensure that they are able to get care when they need it [37]. 
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The age of onset criterion has been changed from “symptoms before age 7 years” to 
“prior to age 12”. The symptom threshold has also been changed to reflect clinically 
significant ADHD impairment in adults. For an adult diagnosis to be made, the patient 
only needs to meet five symptoms (instead of six for children) in either of the two 
symptom domains (inattention and hyperactivity-impulsivity). 
 
1.1.4 Neurobiology 
The developmentally inappropriate levels of inattention and hyperactivity-impulsivity 
in ADHD patients could reflect a course of brain development that is atypical or typical 
but delayed. The primary source of evidence supporting the neurodevelopmental basis 
of ADHD has come from neuroimaging studies. Structural magnetic resonance imaging 
studies have found that a variety of brain sub-regions are associated with ADHD, 
including frontal and parietal cortexes, basal ganglia, cerebellum, hippocampus, and 
corpus callosum [38-40]. The most replicated finding is that ADHD is associated with 
smaller volumes of dorsolateral prefrontal cortex, cerebellum, and subcortical 
structures [41,42]. Longitudinal imaging studies have provided evidence that the 
structural abnormalities observed in children with ADHD may be caused by a delay in 
structural maturation [43,44]. Functional magnetic resonance imaging measures the 
activity of brain regions involved in psychological tasks. Meta-analyses of functional 
imaging studies, that compared ADHD patients to controls, indicate hypo-activation 
occurs in the brain system (e.g., frontal-subcortical circuits) involved in executive 
functions [45,46]. Executive functions include neurocognitive processes, such as 
inhibition, working memory, set-shifting, interference control, planning, and sustained 
attention [47]. Deficits in executive functions have been implicated in most of the 
neuropsychological theories about ADHD [48-50].  
 
At the molecular level, evidence from animal and psychopharmacological studies 
suggests that dopaminergic, adrenergic and possibly serotonergic systems are involved 
in the pathophysiology of ADHD [51,52]. In general, alterations in any single brain 
region or neurotransmitter system are unlikely to explain the heterogenetic nature of 
ADHD. Rather, ADHD is increasingly being recognized as a disorder underlaid by 
dysfunction in multiple neuronal systems [46,53].  
 
1.2 ORIGINS 
1.2.1 Genetic risk factors 
For many decades, studies have shown that ADHD runs in families, regardless of the 
changes in terminology and assessment approaches [54-56]. Family studies have 
identified two to eightfold increases in the risk of ADHD in first degree relatives of 
children with ADHD [57]. Because of its strong familial nature, genetically informative 
studies have been use to separate the genetic and shared environmental effect in the 
familial aggregation of the disorder. 
 
Twin studies have been used to establish the heritability of ADHD, i.e., the degree to 
which ADHD is influenced by genetic factors. The twin method relies on the difference 
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between the within-pair similarities of monozygotic (MZ) twin pairs, who are 
genetically identical, and dizygotic (DZ) twin pairs, who share on average 50% of their 
segregating genes [58]. The extent to which MZ twins are more similar than DZ twins 
can be used to compute heritability (see section 4.1.1). Numerous twin studies have 
been conducted on childhood ADHD in different countries and cultures, using varied 
definitions of ADHD. The mean estimate of heritability of ADHD in children has been 
found to be 0.76 [57], suggesting that genes have a substantial role in the development 
of ADHD. Adoption studies of ADHD also demonstrated a genetic etiology, by 
showing that the biological relatives of ADHD children have a greater risk of ADHD 
than the adoptive (i.e., non-biological) relatives of adopted ADHD children [57].  
 
In contrast to the consistently high heritability estimate of ADHD in children, the few 
twin studies that have investigated ADHD in adults, which all relied on self-ratings, 
found lower heritability, with estimates between 30% and 40% [59-62]. However, it is 
still unclear whether these self-report studies indicate a true difference in the heritability 
of childhood and adult ADHD, or they reflect a rater bias [63].  
 
Given the high heritability of ADHD, considerable efforts have been, and still are 
being, made to search for specific susceptibility genes for ADHD. Two main 
approaches have been used: 1) candidate gene studies, which are often considered as 
“hypothesis-driven”, and test one or more genetic variants that might be biologically 
relevant; 2) genome-wide association studies (GWAS), which are “hypothesis-free” 
and search the whole genome for common and rare genetic variants. Within the large 
and conflicting literature on candidate gene associations for ADHD, a small number 
have been shown significant associations withstanding replication and meta-analysis, 
including genes involved in the dopaminergic pathway (DAT1, DRD4, DRD5) and 
others (5HTT, HTR1B, and SNAP2) [57,64]. The few GWAS on ADHD that have been 
performed to date have failed to identify any common genetic variant that reaches the 
genome-wide significance level (p= 5×10
-8
; the statistical threshold is set this high to 
correct multiple testing) [65-67]. Recent findings suggest that rare chromosomal 
deletions and duplications, known as copy number variants, are associated with 
neurodevelopmental disorders, including ADHD [68,69]. It is now generally accepted 
that we should not expect to find a single or even a few genes responsible for ADHD, 
since most psychiatric disorders involve many genetic variants (and environmental 
factors) that only make small contributions to their etiology [70]. 
 
1.2.2 Environmental risk factors 
Many environmental factors have been proposed as risk factors for ADHD, including 
pre- and perinatal factors (e.g., maternal smoking during pregnancy [SDP], low birth 
weight, and young maternal age), environmental toxins (e.g., lead and polychlorinated 
biphenyls), dietary factors (e.g., food additives), and psychosocial adversity (e.g., low 
income and parent-child conflict) [71,72]. However, many of these studies simply 
measured the associations between potential risk factor and ADHD, and it has been 
difficult to determine which risk factors are causal [73-75]. As correlation does not 
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necessarily equal causation, extreme caution is needed to interpret associations from 
observational studies. Most putative environmental factors (e.g., SDP, young maternal 
age) are not randomly distributed and could arise because of selection factors (e.g., low 
family income) [76], and these selection factors (or usually called “confounder”) may 
account for observed association between both putative environmental factors and 
ADHD. Without a clear understanding of their causal effects, interventions could target 
the wrong factors, and ignore potentially important risk factors. 
 
While a randomized controlled trial (RCT) is considered as the gold standard for 
evaluating the causal effect of modifiable environmental factors, it is not always 
feasible or ethical. One appealing alternative is quasi-experimental design that can tease 
apart co-occurring risk mechanisms and account for unmeasured genetic and 
environmental confounds [77-79] (see section 4.1.2). One of the most studied prenatal 
risk factors for ADHD is SDP [80]. It is theoretically compelling as a causal risk factor 
because nicotinic receptors modulate dopaminergic activity, which is believed to be 
involved in the pathophysiology of ADHD. However, this causal hypothesis has been 
challenged by growing evidence from studies using genetically-informative designs 
[81,82]. By comparing siblings discordantly exposed to SDP, these studies found that 
the association between SDP and offspring ADHD is attenuated towards null, which 
suggest this association is primarily explained by familial (genetic or environmental) 
confounding. 
 
1.3 CONSEQUENCES 
ADHD predicts many clinically meaningful outcomes. Research has shown that ADHD 
is associated with a high risk of comorbidity with other psychiatric disorders [83-85]. 
ADHD is also associated with functional impairments such as school dysfunction, peer 
problems, family conflict, poor occupational performance, accidental injuries, anti-
social behavior, and traffic accidents [33,86], all of which exert an enormous burden on 
the patients, families and society [87,88].   
 
1.3.1 Psychiatric comorbidity 
ADHD exhibits a high level of comorbidity with a wide variety of other psychiatric and 
developmental disorders. In children and adolescents, psychiatric disorders comorbid 
with ADHD include oppositional defiant disorder (ODD), conduct disorder (CD), 
mood disorder (both unipolar and bipolar), anxiety disorder, and substance use disorder 
(SUD) [3,89]. CD/ODD is the most commonly comorbid condition of childhood 
ADHD, and has been found to co-occur in 30% to 50% of cases [85]. There are also 
well-established associations between ADHD and intellectual disability, specific 
learning and developmental problems, and autistic spectrum disorders [90-93].  
 
Much of the early research on comorbidity, however, is limited by its reliance on 
correlational and cross-sectional designs. For example, the cumulative results of 
retrospective studies of adults and prospective studies of children indicate that children 
and adolescents with ADHD are at increased risk of SUD [94-96]. However, it has long 
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been controversial whether ADHD is an independent risk factor for SUD, or the risk is 
due to comorbid CD. Moreover, results from family and twin studies suggest there 
might be a common genetic component that explains the overlap between ADHD and 
its comorbid disorders [97-99]. Longitudinal studies with a genetically informative 
sample may provide insight into the potential mechanisms that explain how ADHD is 
associated with other comorbid problems. 
 
1.3.2 Functional impairment 
Individuals with ADHD are affected by the disorder throughout their lifetimes. 
Children diagnosed with ADHD have been shown to be more likely to experience 
academic failure than their non-ADHD peers; they are more likely to have poor grades, 
poor reading and math test scores, or grade retention, and are less likely to graduate 
[100,101]. Children with ADHD have also been shown to have difficulties in family 
and peer relationships [102], and hive a high predisposition for accidental injury 
[103,104]. 
 
For those adolescents and adults with persistent ADHD, educational difficulties 
continue, and problems in the areas of occupational and social activity, driving, and 
sexual relationships emerge. Individuals with ADHD have been shown to be more 
likely to be unemployed and have lower income compared to controls [105]. ADHD 
may interfere with driving competence, predisposing those with ADHD to impaired 
driving performance and increased risk for adverse driving outcomes [106,107]. 
Adolescents with ADHD begin having sexual intercourse early, and have difficulties in 
maintaining partnership [33]. 
 
Although the ADHD-related impairments have been well-documented in the past 
literatures, some methodological shortcomings (e.g., small sample sizes, absence of 
females, inadequate controls, and referral bias) raise uncertainty about the magnitude of 
these associations [107,108]. In addition, studies using more recent data are needed in 
lights of the increasing diagnoses of ADHD [22]. 
 
1.4 TREATMENT OF ADHD 
The treatment of ADHD involves two major domains: non-pharmacological treatment 
and pharmacological treatment. 
 
Non-pharmacological treatments include different forms of psychosocial interventions. 
Behavior modification (e.g., clinical behavior therapy, contingency management) 
which uses reward and response cost to increase desired behaviors and decrease 
undesirable behaviors, has been shown to effectively improve the functioning of 
children with ADHD [109,110]. Behavior modification typical involves working with 
parents and teachers to program behavioral contingencies into the child's home, school, 
and recreational environments. Cognitive-behavioral therapy has shown positive results 
in adults with ADHD [111]. Non-pharmacological treatments are used by themselves 
or in combination with pharmacological treatment.  
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The Swedish national guidelines for medication of ADHD, issued by the Swedish 
National Board of Health and Welfare in 2002, stated that pharmacological treatment 
should be reserved for cases in which other supportive interventions have failed. In 
many other countries, however, pharmacological treatment is the mainstay for 
treatment of children, adolescents and adults with ADHD [112]. Stimulants are the 
front-line medications for ADHD, which include methylphenidate (Ritalin, Concerta 
and others), dexmethylphenidate (Dexedrine and others), mixed amphetamine salts 
(Adderall), and lisdexamfetamine (Vyvanse). Non-stimulant medications (e.g., 
atomoxetine) have also been used to treat ADHD, although their efficacy seems to be 
slightly lower than that of stimulants [113,114]. An important development of ADHD 
medication is the formulation of extended-release stimulants, which greatly reduce 
untoward peak adverse effect and eliminate afternoon rebound [112].  
 
Findings from RCTs indicate that ADHD medications have beneficial short-term 
effects on the core symptoms of ADHD [51,115-120], and suggest they may contribute 
to improvements in multiple related domains [121]. A recent population-based study 
also suggested reductions in criminality while under medication [122]. However, the 
effect of ADHD medication is still not adequately studied in many other important 
areas, such as transport accidents.  
 
The possible beneficial effects of medication on short-term behavior have to be 
carefully weighed against potential adverse effects [123]. The use of stimulant 
medication for ADHD treatment has been one of the most controversial areas in child 
psychiatry. So far, there is no conclusive evidence that careful use of ADHD 
medication is harmful. However, concerns have been expressed over about the long-
term effects of ADHD medication on cardiovascular risk, growth delay, suicide, and 
the development of substance abuse [124].  
 
One big threat to observational studies of the effect of medication is confounding by 
indication [125]. It is possible that patients receiving medication might be different 
from non-medicated patients in a number of ways, such as symptom severity or 
comorbid disorders. Therefore the observed effect of medication might be biased by 
these (confounding) factors. In observational studies, it is rarely possible to measure all 
such potential confounding factors. Ideally, the benefits and risks of ADHD medication 
should be evaluated by RCTs. However, an RCT on the long-term effects of ADHD 
medication is unlikely to be feasible because of practical and ethical reasons. Another 
common problem for ADHD medication is poor medication adherence [126]. This 
problem affects both observation studies and RCTs, and most of the research should be 
interpreted as intention to treat analyses. On the other hand, treatment discontinuation 
also provides opportunities to study the effect of medication using novel designs based 
on observational data [122]. 
 
It should be noted that the rate of ADHD prescription rates has increased substantially 
in Sweden [127] and other countries [128,129]. The use of ADHD medication in 
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Sweden increased 34% per year from 2006 to 2009, on average [127]. Therefore, there 
is a critical need to accurately evaluate the specific benefits and risks of ADHD 
medication, with population-based samples and designs that can explore rare and 
serious outcomes [130,131]. 
 
1.5 SPECIFIC RESEARCH QUESTIONS 
1.5.1 Heritability of ADHD throughout development 
Twin studies based on parent and teacher ratings yield high heritability estimates for 
ADHD symptoms in childhood and adolescence, usually in the range of 70% to 80% 
[57]. In contrast, the few twin studies that have investigated ADHD in adults, which 
relied on self-ratings, have found lower heritability estimates, ranging between 30% 
and 40% [59-62]. However, because there are no published informant or cross-
informant data on adult twins, it is not clear whether results of these studies indicate a 
true difference in the heritability of ADHD in adults compared with children or whether 
they reflect the use of self-ratings in contrast to informant data [63,132]. Family 
studies, showing a high familial loading on ADHD in adults [133], support the latter 
explanation. 
 
Most previous twin studies have used cross-sectional data to estimate heritability at 
different ages and are therefore unable to distinguish stable genetic risk factors that 
influence the disorder over time from genetic factors that emerge during development. 
The few longitudinal twin studies indicated that both stable and dynamic genetic factors 
influenced the development of ADHD [134-137], unfortunately, none of these studies 
followed the twins into adulthood. Knowledge about the developmental structure of 
genetic risk factors for ADHD, from childhood to adulthood, would help to clarify the 
nature of the etiological links between ADHD in children and adults. 
 
In Study I, we applied a longitudinal design with multi-informant data, to explore the 
relative contribution of genetic and environmental influences on attention problems (an 
index of ADHD) from childhood to early adulthood. The use of multi-informant data 
allowed us to explore whether previous reports of low heritability for ADHD in adults 
are best explained by rater effects or developmental effects. The longitudinal design 
allowed us to examine the continuity and change in genetic and environmental risk 
factors throughout development. 
 
1.5.2 Young maternal age and offspring ADHD 
An important, but less explored, risk factor for ADHD is young maternal age (the age 
of the mother when giving birth). Teenage childbearing is recognized as an important 
public health concern worldwide, and it is associated with a wide range of negative 
developmental outcomes for offspring [138], in particular antisocial behaviors 
[139,140]. Despite the high comorbidity between ADHD and antisocial behaviors 
[141,142], few studies have examined the association between young maternal age and 
offspring ADHD.  
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Two studies have shown that young maternal age is associated with increased risk for 
ADHD [143,144]. However, both of the studies reported only correlations, and the 
mechanisms underlying this observed association are poorly understood. One important 
issue, when studying maternal age, is to distinguish between maternal age at current 
birth (MACB) and maternal age at first birth (MAFB); i.e., whether maternal age at 
childbearing have offspring-specific effects, or offspring-shared effects.  
 
If all children born to young mothers have a similar increased risk of ADHD, then this 
suggests that maternal age at childbearing has offspring-shared effects, and MAFB 
represents a more relevant index than MACB. MAFB could be causally associated with 
ADHD in all offspring. Early childbearing may disrupt the developmental trajectory of 
young mothers, leading to poverty, poor education, and ineffective parenting [145], 
which increase the risk for ADHD in offspring. Alternatively, MAFB might not be 
causally associated with offspring ADHD. Rather it may be a marker for genetic or 
environmental selection factors that are causally associated with both maternal age and 
offspring ADHD. Putative environmental risk factors (e.g., young maternal age) could 
be influenced by genetic factors, which would be transmitted from parents to their 
offspring and account for the poor outcome in offspring, a phenomenon known as 
passive gene-environmental correlation (rGE) [146,147]. 
 
Study II attempted to explore the mechanism underlying the association between early 
maternal age at childbearing and offspring ADHD. The study used quasi-experimental 
designs to try to understand how early life circumstances affect child development. 
 
1.5.3 ADHD and early-onset substance use 
Research has documented that children with ADHD are at increased risk of SUD [94-
96]. However, the mechanism underlying this association is still unclear because of 
several issues. First, it is unclear whether ADHD is an independent risk factor for SUD, 
or the association reflects its comorbidity with CD [148]. Second, it is unclear which 
symptom dimension of ADHD (inattention [IN] or hyperactivity-impulsivity [HI]) 
predicts SUD. Some studies suggested that IN predicts SUD [96,149,150], which is in 
line with the self-medication hypothesis that patients with ADHD would use nicotine to 
compensate attention and executive deficits [151-153]. In contrast, a population-based 
prospective study found HI, independent of inattention and CD, predicts early-onset 
tobacco, alcohol, and illicit drug use. Third, it is unclear to what extent the observed 
association is influenced by common genetic and environmental contributions. Both 
ADHD [57] and substance use [154] are heritable, and the association between ADHD 
and substance use could be explained by common genetic influences [98,99]. 
 
In Study III, we tried to address these issues by investigating the longitudinal 
relationship between the two symptom dimensions of ADHD and early-onset substance 
use in a large population-based twin sample, taking CD into account. Early-onset 
substance use is an important, but less studied, problem, because early adolescence is a 
sensitive developmental period for exposure to substances [154], and because early-
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onset substance use is a strong predictor of development of SUD and other health 
problems [155,156]. 
 
1.5.4 ADHD, transport accidents, and the effect of medication 
According to report of the World Health Organization (WHO), approximately 1.3 
million individuals are killed each year by traffic accidents, and 50 million are injured 
or disabled [157]. An emerging literature has documented an association between 
ADHD and transport accidents [107,108,158-160]. However, small sample sizes, lack 
of females in the studies, absence of objective measures, inadequate controls, and 
referral bias raise uncertainty about the reported magnitude of the associations [106, 
109]. 
 
A few studies have explored whether ADHD medication improves driving ability in 
virtual-reality driving simulators [107,159,161], however, the extent to which these 
effects generalize to real-world situations is unclear. Because decisions regarding the 
prescription of ADHD medication need to consider the effect sizes of the benefits and 
risks of medication at the population level [123,162], a population-based prospective 
study with measures of transport accidents in real life (i.e., injuries and deaths) is 
needed. 
 
In Study IV, we used data from population-based registers in Sweden to assess two 
research questions: First, what is the magnitude of the association between ADHD and 
serious transport accidents (injuries and deaths); second, to what extent ADHD 
medication influences the risk of transport accidents among ADHD patients. 
 
1.5.5 ADHD medication and risk of substance abuse 
There have been concerns over the long-term effects of medication on the development 
of substance abuse [163,164].  
 
It is well-established that ADHD is associated with an increased risk for substance 
abuse [95,165], and this comorbidity has led to the hypothesis that this risk is mediated, 
at least in part by exposure to stimulant medication. This hypothesis is grounded by 
findings from animal studies that animals exposed to stimulants become “sensitized”, a 
phenomenon of increased response to an addictive substance after repeated exposure 
[166,167]. Although many studies seem to find no or possibly protective effects of 
ADHD medication on substance use [168-172], their sample sizes were limited. More 
evidence is critical to help ADHD patients, and their families and clinicians to make 
treatment decisions. 
 
In Study IV, we used data from population-based registers in Sweden to test the 
hypothesis that stimulant ADHD medication is associated with an increased risk for 
long-term substance abuse. 
 14 
2 AIMS 
The general aim of this thesis was to investigate how genetic and environmental factors 
contribute to the development of ADHD, as well as to investigate the consequences of 
ADHD and potential influences of ADHD medication. 
 
The specific aims were: 
 
 To explore the relative contribution of genetic and environmental influences on 
symptoms of attention problems from childhood to early adulthood. 
 
 To explore the mechanisms that underlying the association between early 
maternal age at childbearing and offspring ADHD, using a genetically-
informative design. 
 
 To investigate how the two symptom dimensions of ADHD (hyperactivity-
impulsivity and inattention) are associated with early-onset substance use, and 
the extent to which the association is influenced by genetic and environmental 
factors. 
 
 To estimate the association between ADHD and the risk of serious transport 
accidents, and to explore the extent to which ADHD medication influences this 
risk among ADHD patients. 
 
 To verify whether stimulant ADHD medication is associated with risk for long-
term substance abuse. 
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3 STUDY SAMPLES 
3.1 THE SWEDISH TWIN STUDY OF CHILD AND ADOLESCENT 
DEVELOPMENT 
3.1.1 Sample and Response Rate 
The data used in Study I and Study III comes from the Twin study of CHild and 
Adolescent Development (TCHAD) [173]. The target sample consisted of all the 1,480 
twin pairs born in Sweden between May 1985 and December 1986 who were alive and 
residing in Sweden in 1994. The twins were identified through the population-based 
Swedish Twin Registry (STR) [174]. The twins and their parents had been contacted 
via questionnaires mailed in four different waves: wave 1 in 1994 (childhood, ages 8–
9); wave 2 in 1999 (early adolescence, ages 13–14); wave 3 in 2002 (late adolescence, 
ages 16–17); and wave 4 in 2005 (early adulthood, ages 19–20). 
 
The response rates for the parent questionnaires were 75% (n=1,109) in wave 1, 73% 
(n=1,063) in wave 2, 74% (n=1,067) in wave 3. In wave 4, both parents were 
approached separately, and responses were obtained from at least 1 of the parents for 
1,158 twins. A majority of the parent-reported information was supplied by the twins’ 
mothers (75%-90%). The response rates for the twin questionnaires were 78% 
(n=2,236) in wave 2, 82% (n=2,369) in wave 3, and 59% (n=1,705) in wave 4. 
 
3.1.2 Zygosity determination  
Zygosity was assessed by DNA testing. The twins’ DNA was extracted from saliva 
samples using an Ora-Gene DNA self-collection kit (DNA Genotek Inc). For twins 
without a DNA sample, zygosity was determined based on an algorithm derived from 
discriminant analyses of twins’ and parents’ responses to validated zygosity 
questionnaires [173]. In cases in which the assignments were questionable (n=100, 
3.4%), the zygosity was set to unknown, and the twins were excluded from the 
analyses. It should be noted that in earlier reports from the TCHAD study, other 
algorithms were used for zygosity classification. However, we have used the best 
available zygosity diagnose at each time point, and the variations between the different 
methods are small and of minor importance.  
 
3.1.3 Measures 
TCHAD is a longitudinal study of how genes and environments contribute to the 
development of health and behavioral problems from childhood to adulthood. Major 
domains of measures (in different waves) included socio-demographic factors, physical 
health, competence, behavior, personality, externalizing/internalizing behavior and 
symptoms, life events and relationships. 
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3.1.3.1 DSM-based symptoms of ADHD 
A checklist of ADHD symptoms, with 21-24 items based on DSM, was completed by 
parents at waves 1, 2, and 3. The parents were asked to mark (yes or no) any inattention 
(IN) or hyperactivity-impulsivity (HI) symptom that persisted for at least six months. 
Because of changes in the DSM during the follow-up period, the complete set of all 18 
DSM-IV symptoms were not included in each wave. In Study III, we used parent-rated 
ADHD symptoms when the twins were 8 to 9 and 13-14 years old. In wave 1, parent 
rated ADHD symptoms via a checklist of 14 items based on the DSM-IV (6 IN 
symptoms and 8 HI symptoms) [134]. In wave 2, the checklist included 17 items based 
on the DSM-IV (8 IN symptoms and 9 HI symptoms). The internal consistency (alpha 
reliability) for IN was 0.78 in wave 1 and 0.74 in wave 2. The alpha reliability for HI 
was estimated as 0.77 in both waves. Our ADHD instrument has not been formally 
validated as a measure, but has been used in several prior epidemiological studies by 
our research group. Results from these studies were consistent with well-established 
findings in the ADHD literature [32,134,175,176].  
 
3.1.3.2 Child Behavior Checklist/Youth Self-report 
Parents completed the Child Behavior Checklist (CBCL) [177] when the twins were 8 
to 17 years old, and the Adult Behavior Checklist (ABCL) [178] when the twins were 
19 to 20 years old. The twins completed the Youth Self-Report form (YSR) [179] and 
the Adult Self-Report form (ASR) [178] at the corresponding ages. The CBCL, YSR, 
ABCL, and ASR are standardized questionnaires for parents and twins to rate the 
frequency and intensity of behavioral and emotional problems exhibited by the twins 
during the past 6 months. All items were scored on a 3-point scale (0=not true; 
1=sometimes true; and 2=often true). The YSR consists of the same items as those in 
the CBCL. The ABCL and ASR consist of similar or developmentally appropriate 
counterparts of items used in the CBCL and YSR. 
 
In Study I, we used the parents’ ratings and the twins’ self-ratings of Attention 
Problems (AP) scale at ages 8 to 9, 13 to 14, 16 to 17, and 19 to 20 years. The AP scale 
assesses problems related both to inattention and hyperactivity-impulsivity and has 
been found to predict ADHD status [180-182]. We therefore consider the AP scale to 
be a measure of ADHD symptoms.  
 
In Study III, we created conduct problem behavior (CPB) sum scores based on the 15 
items included in the CBCL/6-18-DSM-oriented conduct problems scale. The internal 
consistency (alpha reliability) was 0.80 at both waves. The CBCL DSM-oriented scales 
were initially constructed through agreements in experts’ ratings regarding the 
consistency between CBCL items and specific DSM-IV diagnostic criteria [183].  
 
The psychometric properties of these scales have been examined in both population-
based and clinical samples, presenting good reliability, as well as convergent and 
discriminative validity [177-179,183-185].  
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3.1.4 Representativeness of the sample 
Previous attrition analyses across the waves of TCHAD found no significant 
differences in sex ratio, family social economic status, or the number of ADHD 
symptoms in wave 1 when comparing participants and non-participants in wave 2 
[175]. Furthermore, follow-back analyses revealed that there were no significant 
differences in wave 2 data between participants and nonparticipants in wave 1[186]. 
However, there is some evidence of selective attrition in wave 4; attrition rates at age 
19-20 years were higher for individuals with higher levels of childhood ADHD 
symptoms, and for boys. Thus, it is possible that the variation of ADHD at extreme 
level is truncated and the results may not be generalizable to cases with the most 
extreme cases of ADHD. However, it is unlikely that attrition biased the genetic or 
environmental parameter estimates, because the intra-class correlations at baseline (age 
8-9 years) were similar among the longitudinal responders and non-responders. 
 
3.2 SWEDISH NATIOANL REGISTERS 
The data used in Study II, Study IV and Study V come from linkage of national 
population-based registers in Sweden, with unique personal identification numbers, 
which enabled accurate linkage [187].  
 
3.2.1 National Patient Register 
The National Patient Register (NPR), kept by the National Board of Health and 
Welfare, provides data on all hospital admissions in Sweden. Every record has a 
discharge date, a primary discharge diagnosis and up to eight secondary diagnoses 
assigned by the treating medical doctor according to the ICD: ICD-8 for 1969-1986, 
ICD-9 for 1987-1996 and ICD-10 from 1997 [8]. The NPR has national coverage of 
psychiatric in-patient care since 1973, and information on psychiatric out-patient care 
since 2001. Information from the NPR was used to identify ADHD cases (the outcome 
in Study II, study population in Study IV and V), emergency hospital care due to 
transport accidents (the outcome in Study IV), hospital visits due to psychoactive 
substance use (the outcome in Study V), and other disease diagnosis used as covariates 
in the different studies. 
 
3.2.2 Multi-Generation Register 
The Multi-Generation Register (MGR), held by Statistics Sweden, contains information 
about biological and adoptive relationships for more than 13 million individuals born 
1932-2009 and registered as living in Sweden at any time during 1961-2009 [188]. The 
register is part of the Total Population Register (TPR), which collects information from 
the national registration records maintained by the National Tax Board. For each target 
individual, the register includes information on the identification number of biological 
parents and adoptive parents, if appropriate. The registry also includes date of birth 
information for each individual. Information from the MGR was used to identify 
different types of family structures used in Study II, including siblings and children of 
siblings/twins. 
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3.2.3 Medical Birth Register 
The Medical Birth Register (MBR), kept by the National Board of Health and Welfare, 
includes data on all pregnancy outcomes and complications in Sweden from 1973 
onwards. It includes data on newborn children and their mothers from more than 99% 
of births in Sweden [189]. The register includes detailed demographic and pregnancy 
information, including maternal age at childbirth, maternal living situation, maternal 
smoking during pregnancy, birth order of the child, the infant’s physical attributes at 
birth, pregnancy complications, and delivery complications. Information from the MBR 
was used to obtain maternal age at childbirth (the exposure in Study II), and other 
covariates in Study II. 
 
3.2.4 Prescribed Drug Register 
The Prescribed Drug Register (PDR), also kept by the National Board of Health and 
Welfare, includes data on all prescribed drugs dispensed at pharmacies in Sweden. It 
contains information regarding drug identity, according to the Anatomical Therapeutic 
Chemical classification system (ATC), quantity and dosage of the prescribed drug, date 
of prescription/dispensing, and specific patient information (gender, age and residential 
area). The register has covered the entire population of Sweden since July 2005, and the 
identity of the patients is available for over 99.7% of the population [190]. Information 
from the PDR was mainly used to identify use of ADHD medication (the exposure in 
Study IV and V, ATC code: N06BA04, N06BA01, N06BA02, and N06BA09). 
 
3.2.5 Causes of Death Register 
The Cause of Death Register (CoD), also kept by the National Board of Health and 
Welfare, includes mandatorily reported information from death certificates for all 
deceased individuals. It contains data on the principal and contributing causes of death, 
coded according to the ICD. The register was established in 1952, and it contains 
complete information on causes of death since 1961. Information from the CoD was 
used to identify death resulting from transport accidents (the outcome in Study IV), 
death resulting from psychoactive substance use (the outcome in Study V), and used as 
end points in all follow-ups.  
 
Data from the Migration Register, the Crime Register and the Integrated Database for 
Labor Market Research were also used in different studies to provide information on 
migration, crime records and socio-demographic variables (e.g., civil, employment, and 
education status). 
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4 STUDY DESIGNS AND METHODS 
4.1 GENERAL METHODS 
4.1.1 Twin methodology 
The pioneering study on twins dates back to 1875, when Sir Francis Galton published 
an article titled “The history of twins, as a criterion of the relative powers of nature and 
nurture” [191]. Since then, the twin methodology has been widely used as a ‘natural 
experiment’ in research to disentangle and to quantify the contributions of genetic and 
environmental effects on human complex traits. The twin method relies on the different 
within-pair similarities between MZ twin pairs, who are genetically identical, and DZ 
twin pairs, who share 50% of their segregating genes, on average. By comparing the 
within-pair similarities, one can infer the presence of genetic and environmental 
influences on a trait. A genetic influence is indicated if twin similarity is greater among 
MZ than DZ twin pairs. 
 
In the 1970s, research began to employ variance partitioning using maximum 
likelihood methods [192]. From biometric genetic theory, it is possible to write 
structural equations that relate the observed traits of twins to their underlying genetic 
and environmental influences [193]. In the classic twin model, the variance of an 
observed phenotype can be decomposed into three variance components: additive 
genetic factors (A), shared environmental factors (C), and non-shared environmental 
factors (E). Shared environmental factors are non-genetic influences that make the 
twins similar, and non-shared environmental factors refer to non-genetic influences that 
make the twins different. The contribution of these ‘latent’ factors can be estimated by 
comparing the similarity between MZ twins and DZ twins. Figure 2 illustrates the 
classic ACE model for analyzing twin data.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The genetic correlation between twin pairs is 1 for MZ twins, and 0.5 for same sex DZ 
twins. The shared environmental correlation is 1 for both MZ and DZ twins, under the 
Figure 2. Classic ACE model for analyzing twin data. 
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equal environment assumption. The non-shared environmental correlation is 0, by 
definition.  
 
Heritability is defined as the proportion of phenotypic variance among individuals 
attributable to genetic factors [58]. It is important to note that heritability does not refer 
to the genetic composition of any individual. Rather, it refers to the genetic contribution 
to the difference between individuals in a defined population. 
 
During the past decade, twin research has moved from simple univariate analyses to 
more complex longitudinal and multivariate analyses. In Study I, multivariate analysis 
of longitudinal data was used to study the development of ADHD over time. In Study 
III, multivariate analysis was used to explore the causes of comorbidity between 
disorders. By including additional family types, it was also possible to study the 
intergeneration transmission (Study II). 
 
The structural equation modeling (SEM) packages Mx [194] and OpenMx in R [195] 
were used to perform full information maximum-likelihood model-fitting with raw 
data. A liability threshold model was applied to categorical variables, which assumes 
that the ordered categories reflect an imprecise measurement of an underlying normal 
distribution of liability [193]. Traditionally, goodness-of-fit of models are assessed by 
likelihood ratio tests. More recently, the Bayesian information criterion, which 
measures model fit relative to parsimony, has been widely used for multivariate 
behavior genetic models [196]. 
 
4.1.2 Quasi-experimental designs 
Determination of the causal connections between modifiable risk factors and outcomes 
is one of the key challenges in the field of developmental psychopathology [76]. Tests 
of causal hypotheses often require prospective longitudinal studies in which reverse 
causation is not possible. In addition, tests of causal hypotheses must be cautious about 
the possibility that genetic and environmental selection factors account for non-random 
exposure of environmental risk factor and, thereby, confound the associations between 
exposure and outcomes [73,146]. Quasi-experimental designs can be used to test causal 
hypotheses by ruling out plausible alternative explanations.  
 
4.1.2.1 Genetically informative design 
The comparison of differentially exposed full siblings provides a rigorous test of causal 
hypotheses about early risk factors because the design can rule out unmeasured 
confounds that limit the comparison of unrelated individuals, including all 
environmental influences that are shared by siblings within nuclear families and all 
genetic factors [197]. Sibling comparisons rule out confounded genetic risk transmitted 
by mothers (shared genetic liability due to passive rGE) because the process of meiosis 
randomly distributes genes across siblings. Whereas the comparison of siblings controls 
for environmental factors shared by all siblings in a nuclear family, the comparison of 
differentially exposed cousins controls for environmental factors that influence all 
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offspring in an extended family. Full cousins (offspring of full siblings) share 12.5% of 
their genetic makeup. Thus, the comparison of full siblings also partially controls some 
genetic selection factors. This approach does not control for confounds as well as the 
comparison of full siblings, but is useful for studying familial-level factors (e.g., 
maternal age at first childbirth in Study II). In addition to sibling comparisons and 
cousin comparisons, comparisons of half-siblings, half-cousins, and children of twins 
provide opportunities to replicate the findings, and to test many of the assumptions 
inherent in each design. The different groups of relatives used in different designs are 
shown in Figure 3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sibling/cousin comparisons are performed by fitting fixed-effect models [198], under 
certain assumptions [199]. If an environmental risk is causally associated with an 
outcome, then the association should remain in sibling/cousin comparisons. If the 
association attenuates or disappears, this suggests that the association between 
environmental the risk factor and the outcome is, at least partly, due to unmeasured 
genetic or environmental confounding. 
 
4.1.2.2 Time-series within-individual design 
Time-series within-individual analysis represents another powerful quasi-experimental 
design that can be used to study exposures that change over time. In such design, 
individual serves as his or her own control, and the risk of outcome is compared 
between exposed periods of time (e.g., treatment) and unexposed periods (e.g., no 
treatment). As such, the within-individual estimate automatically adjusts for 
confounding by all unmeasured covariates that are constant within each individual 
during follow-up (e.g. genetic predisposition and early environments).  
 
Figure 3. Schematic of groups of relatives used in the studies. 
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This is a useful approach to study the effects of medication, especially when RCTs are 
not feasible. In Study IV and V, we used this approach to study the effect of ADHD 
medication on concomitant transport accidents and substance abuse. The use of ADHD 
medication was treated as a time-varying exposure. Within-individual analyses were 
performed using stratified Cox regression [198], with each individual entering as a 
separate stratum. 
 
4.2 STUDY I 
Study I was based on data from TCHAD sample. Parent ratings and twin self-ratings of 
AP were measured at ages 8 to 9, 13 to 14, 16 to 17, and 19 to 20 years. Because item 
performance could vary by rater, sex, or age, we created factor scores of AP separately 
for each combination of these factors (e.g., parent ratings of boys at age 8-9 years) 
[200]. Factor loadings were calculated for each item in the program Mplus [201], using 
a robust weighted least squares estimator. 
 
The relative contribution of genetic and environmental influences on symptoms of AP 
from childhood to early adulthood was estimated using longitudinal SEM with multiple 
informants (Figure 4). Both parent- and self-ratings were used as indicators for the 
latent factors of AP (AP1 to AP4). The paths λp and λs reflect the degree to which parent 
ratings and self-ratings of AP represent the latent AP factors. The genetic and 
environmental influences on AP1 to AP4 are modeled by Cholesky decomposition. The 
factor structure depicted by latent factors F1 through F4 is implemented for the three 
sources of variance A, C and E. This developmentally informative approach divides 
genetic risk of AP1 to AP4 into four factors (F1–F4). The model also contains two rater-
specific common factors for parent ratings (Fp) and self-ratings (Fs). These factors 
allow the model to estimate the genetic and environmental influences on the ratings that 
are unique to the parents or the children. The remaining part of the phenotypic variance 
is modeled as rater-specific error effects (Rp1-Rs4).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. A longitudinal twin model with multiple informants for Attention Problems. 
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4.3 STUDY II 
The association between maternal age at childbirth and offspring’s ADHD was studied 
using genetically-informative data from Swedish national registries. We studied a 
cohort of children born in Sweden between 1988 and 2003, consisting of 1,640,694 
newborn children identified from the MBR. We excluded those children who had 
severe congenital malformations (n = 59,390), who were from multiple births or still-
born, who died or emigrated before age 3 or year 2001, and who received an ADHD 
diagnosis before age 3. The final sample included 1,495,543 eligible individuals 
(91.2% of the targeted population), which were offspring of 896,389 mothers. Among 
the full sample, we identified 988,625 full siblings from 443,555 mothers. We further 
identified children of full sister mothers, maternal or paternal half-sister mothers, MZ 
or DZ twin mothers. 
 
Maternal age at current birth (MACB) was obtained from the MBR. By linking to the 
MGR, we also obtained maternal age at first birth (MAFB) for each mother. Since most 
studies have focused on the distinction between teenage and adult childbearing [138], 
we used this binary classification to be consistent with previous research. The binary 
variable of MACB / MAFB was defined as teenage childbearing if the mother was less 
than 20 years old at current/first child birth, and adult childbearing if the mother was 20 
years of age or older. Children who were diagnosed with ADHD, according to the NPR 
or treated with ADHD mediation, according to the PDR, were identified as ADHD 
cases. In total, we identified 30,674 children with ADHD from these two registers, and 
the date of diagnosis was defined as the date of first record in any registers. 
 
The extent to which MACB or MAFB is associated with offspring ADHD was 
explored using three models. Cox regression was used to deal with the right-censored 
outcome measure. Model1 examined the population-wide association between MACB 
and offspring ADHD. Model 2 examined the population-wide association between 
MACB and offspring ADHD, controlling for MAFB. Model 3 tested the effect of 
MACB versus MAFB using sibling comparison (see section 4.1.2.1). The association 
between MAFB and ADHD in offspring was explored using two models. Model 4 
examined the population-wide association between MAFB and offspring ADHD. 
Model 5 estimated the association between MAFB and offspring ADHD using cousin 
comparisons. To quantify the magnitude of the different processes explaining the 
observed association between MAFB and offspring ADHD, we used a children of 
siblings (CoS) model -- a SEM with multiple groups of relatives. 
 
4.4 STUDY III 
Study III used data from the TCHAD sample. We used parent reports of ADHD 
symptoms and CPB (index for CD) from wave 1 and wave 2, and self-report of 
substance use from wave 2. Substance use at age 13 -14 was assessed using self-
reports, which were adapted from the Finnish longitudinal study of adolescent twins 
[202]. The measures were categorized into three levels for tobacco and alcohol use 
(“never”, “sometimes”, and “often” use), and two levels for illicit drug use (“never” 
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and “ever” use). Importantly, there was no item overlap between these measures 
(ADHD, CPB and substance use). 
 
We used multinomial logistic regression to investigate the association between 
inattention and hyperactivity-impulsivity symptoms in childhood and substance use in 
early adolescence. The “never use” category of substance use was used as a reference 
group in all multinomial logistic regression models. Odds ratios (OR) with 95% 
confidence intervals (CI) were estimated using generalized estimating equations 
models, which allowed us to account for the dependent nature of the twin observations. 
A bivariate correlated factors model (Figure 5) was used to estimate the genetic 
correlation (rg), the shared environment correlation (rc), and the non-shared 
environment correlation (re) between ADHD symptoms and substance use. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.5 STUDY IV 
In Study IV, we identified all individuals born between 1960 and 1988 with at least one 
diagnosis of ADHD in the NPR since 2001 (N= 17,408). These patients were followed 
from 1/1/2006 to 12/31/2009 (48 months) for any serious transport accident. A non-
ADHD general population sample, matched 1 to 10 for age, sex, and residential area at 
the time of the diagnosis was extracted from the TPR.  
 
The PDR was used to obtain information on all prescribed medications since July 2005. 
In accordance with previous studies [122,127,203], an individual was defined as “under 
medication” during the interval between two dispensed prescriptions (picked up by the 
individuals themselves, family members, or health care staff) of ADHD medication, 
unless the prescriptions occurred more than six months apart. An individual was 
defined as “off medication” during intervals of six months or more without a 
Figure 5. Path diagram depicting the correlated factors model and liability threshold model. 
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prescription. The main outcome measure was serious transport accident, which was 
identified as admission to an emergency hospital care or death due to transport related 
trauma (ICD-10 code: V01-V99) [160] through the NPR and CoD.  
 
To explore the association between ADHD and serious transport accidents, we first 
compared the rate of accidents between individuals with and without ADHD using Cox 
regression. Second, we included measured covariates in the model to control for 
confounding. To investigate the association between ADHD medication and accidents 
among ADHD patients, we initially used ordinary between-individual Cox regression, 
with robust standard errors accounting for the correlations between time periods within 
the same individual. Next, within-individual analyses were performed using stratified 
Cox regression (see section 4.1.2.2). 
 
To assess the public health impact of ADHD medication on serious transport accidents 
we used the population attributable fraction (PAF). In the absence of unmeasured 
confounding, the PAF measures the proportion of accidents that would be eliminated if 
the whole cohort of ADHD patients was medicated during the follow-up.  
 
Because of the gender difference in ADHD [204] and transport accidents [205], all the 
analyses were conducted separately for males and females. Since young males are the 
single most risky demographic group [206], separate analyses were also conducted for 
young and middle-aged adults. 
 
4.6 STUDY V 
In Study V, we identified all individuals between 1960 and 1998 with at least one 
diagnosis of ADHD in the NPR since 2001. We also used the PDR to obtain 
information on prescribed ADHD medications. A non-ADHD general population 
sample, matched 1 to 10 for age, sex, and residential area at the time of the diagnosis 
was also used. 
 
Substance abuse was defined as [207]: (1) hospital visits with diagnoses of mental and 
behavioral disorders due to psychoactive substance use (ICD-10 codes: F11-F16, F19) 
identified from the NPR; (2) deaths due to substance use (ICD-10 codes: F11-F16, F19) 
according the CoD; (3) convictions for a substance related crime according to the 
Crime Register (i.e., making, transfer, possession, or use of illegal substances). 
Substance abuse was treated as a time-to-event variable that could occur repeatedly 
during follow-up. We included only unplanned hospital visits to avoid misclassifying 
planned treatments (e.g., regular hospital visits in treatment programs) as events. 
 
We used Cox-regressions with robust standard errors (to account for the correlations 
between periods within the same individual) to estimate the risk of substance abuse 
during 2009, with stimulant medication status at January 1 2006 as the exposure. First 
we investigated the associations while controlling for sex, and age and medication 
during follow up as time-dependent covariates (Model 1). Second, we controlled for the 
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other covariates at baseline (Model 2). To investigate whether the duration of treatment 
was important, we did separate analyses with the total number of years with ADHD 
medication for 2006-2008 as the exposure. 
 
Finally, to test the effect on short-term abuse we studied the concomitant risk of 
substance abuse. Similar to Study IV, this was done by within-individual analyses, 
using stratified Cox regression.  
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5 RESULTS 
5.1 STUDY I 
A model that included additive genetic (A) and non-shared environmental (E) factors 
and no sex effect provided the best fit with a balance between explanatory power and 
parsimony. Standardized parameter estimates for the genetic and environmental 
contribution (as illustrated in the upper part of Figure 4), along with 95% CIs, are 
shown in Table 3. The relative contributions of genetic and non-shared environmental 
factors are illustrated in Figure 6. 
 
Table 3. Parameter estimates with 95% CIs for the best-fitting model.  
h2, the proportion of variance in AP explained by genetic factors 
e2, the proportion of variance in AP explained by unique environmental factors 
 
The results revealed that genetic factors had a strong influence on AP, as measured by 
the shared view of parent and self-ratings, across the four time points (AP1-AP4). The 
heritability (h
2
) estimates for AP1 to AP4 were 77%, 82%, 82%, and 78%, respectively. 
Unique environmental factors (e
2
) accounted for the remaining part of the variance (i.e., 
18%-23%). The first genetic factor (A1) explained 77% (0.88
2
) of the total variance of 
AP1 at age 8-9, and continued to influence AP, although its influence declined over 
time: it accounted for 41% (0.64
2
) of the variance at age 13-14, 34% (0.59
2
) at age 16-
17, and 24% (0.49
2
) at age 19-20. In addition to the temporally stable genetic factor 
from childhood (age 8-9), new sources of genetic influence on AP emerged at 
subsequent ages: the second genetic factor (A2) explained 41% (0.64
2
) of the variance 
in AP2 at age 13-14; A3 explained 25% (0.51
2
) of the variance in AP3 at age 16-17; and 
A4 explained 30% (0.55
2
) of the variance in AP4 at age 19-20. These new genetic 
factors (i.e., A2 and A3) also continued to impact later times. In contrast to the genetic 
factors, the first unique environmental factor (E1) at age 8-9 attenuated sharply over 
time, while the impact of E2 continued over time, suggesting that some environmental 
factors around puberty have an enduring impact. 
 
 Genetic factors Unique environmental factor 
Factor 
(Age, y) 
Total  
h2 (%) 
A1 A2 A3 A4 
Total  
e2 (%) 
E1 E2 E3 E4 
AP1 
(8-9) 
77 
 
0.88 
(0.76-0.99) 
   
23 
 
0.48 
(0.04-0.65) 
   
AP2 
(13-14) 
82 
 
0.64 
(0.56-0.73) 
0.64 
(0.53-0.71) 
  
18 
 
0.17 
(-0.06-0.48) 
0.39 
(-0.49-0.49) 
  
AP3 
(16-17) 
82 
 
0.59 
(0.50-0.67) 
0.47 
(0.36-0.57) 
0.51 
(0.42-0.57) 
 
18 
 
0.09 
(-0.09-0.48) 
0.39 
(-0.48-0.48) 
0.12 
(-0.28-0.28) 
 
AP4 
(19-20) 
78 
 
0.49 
(0.38-0.60) 
0.39 
(0.24-0.53) 
0.29 
(0.14-0.46) 
0.55 
(0.37-0.66) 
22 
 
-0.12 
(-0.49-0.39) 
0.25 
(0.03-0.58) 
-0.37 
(-0.55-0.55) 
0.01 
(-0.53-0.53) 
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5.2 STUDY II 
We first examined the association between MACB and offspring ADHD. Hazard ratios 
(HRs) with corresponding 95% CIs for MACB are shown in Table 4. Using the binary 
measure, Model 1 found that teenage childbearing was associated with a 57% increased 
risk of offspring ADHD (HR = 1.57). However, the negative association disappeared in 
Model 2 when controlling for MAFB (HR = 0.90) and in model 3 when controlling for 
unmeasured genetic and environmental factors shared by siblings (HR = 0.80). The 
same pattern of results was observed when using the continuous measure of MACB. 
Taken together, the results indicated that offspring born when their mothers were young 
had no increased risk of ADHD, compared with their later-born siblings. Maternal age 
at childbearing had no offspring-specific effects. 
 
Table 4. Association between MACB and offspring ADHD (HRs with 95% CIs). 
MACB Model 1 Model 2 Model 3 
binary 1.57 (1.48-1.67) 0.90 (0.84-0.96) 0.80 (0.70-0.92) 
continuous 0.95 (0.95-0.96) 1.01 (1.00-1.01) 1.02 (1.01-1.03) 
Model 1: Population-wide estimate, adjusted for offspring’s gender, birth order in categories, birth year in 
categories and paternal age at childbirth in categories. 
Model 2: Population-wide estimate, adjusted as Model 1 + mother’s age at first childbirth. 
Model 3: Sibling comparison. 
Figure 6. The proportion of the total variance in latent estimation of attention problems explained by 
genetic factors (A) and unique environmental factors (B) through development. 
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The association between MAFB and offspring ADHD is shown in Table 2. Using the 
binary measure, Model 4 found that teenage childbearing was associated with a 78% 
increased risk of offspring ADHD (HR = 1.78). When using cousin comparison in 
Model 5, the effect of teenage childbearing was somewhat attenuated (HR = 1.33), but 
it remained a significant predictor for offspring ADHD. We obtained the same pattern 
of results using the continuous measure of MAFB. The results indicated that MAFB 
was strongly associated with offspring ADHD, and that part of the association was 
confounded by familial factors.  
 
Table 5. Association between MAFB and offspring ADHD (HRs with 95% CIs). 
MACB Model 4 Model 5 
binary 1.78 (1.72-1.84) 1.33 (1.18-1.50) 
continuous 0.94 (0.93-0.94) 0.97 (0.96-0.99) 
Model 4: Population-wide estimate, adjusted for offspring’s gender, birth order in categories, birth year in 
categories and paternal age at childbirth in categories. 
Model 5: Cousin comparison. 
 
Results of the CoS model showed a moderate heritability of MAFB (47%) and a high 
heritability of ADHD (71%). Extended-family environment had little influence on 
either MAFB or ADHD. A significant genetic correlation was observed between 
MAFB and ADHD (-0.41). Thus, the phenotypic correlation between MAFB and 
offspring ADHD was mainly explained by a correlation between the genetic liability to 
MAFB and the genetic liability to ADHD. This result confirmed and extended findings 
from the cousin comparison, suggesting that the association between MAFB and 
offspring ADHD was not causal and was, instead, mediated largely through genetic 
factors that influence the liability to both MAFB and ADHD. 
 
5.3 STUDY III 
Sample characteristics of ADHD symptoms, CPB and substance use are presented in 
Table 6. Boys had significantly higher levels of HI, IN and CPB than girls. There were 
no significant sex differences in the rate of substance use. 
 
The Table 7 presents the results of regression models using symptoms of HI, IN and 
CPB at age 8–9 to predict substance use at age 13–14. HI significantly predicted both 
“sometimes” and “often” tobacco use. The association of HI with “sometimes” tobacco 
use remained significant when IN and CPB were controlled in the adjusted model; one 
symptom increase of HI at age 8–9 significantly increased the odds of “sometimes” 
tobacco use at age 13–14 by 12%. The significant association between HI and 
“sometimes” alcohol use disappeared in the adjusted model. In the unadjusted models, 
IN predicted “often” tobacco use, “sometimes” and “often” alcohol use, but all 
significant associations disappeared when adjusting for HI and CPB. This indicated that 
the contribution of IN to substance use overlapped with HI and CPB. CPB significantly 
predicted all types of substance use, even after controlling for HI and IN (except for 
drug use).  
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Table 6. Sample Characteristics of ADHD symptom, CPB and Substance Use. 
 Boys Girls p 
HI
 a
 1.16 (1.71) 0.93 (1.47) <0.01 
IN
 a
 0.86 (1.21) 0.54 (0.93) <0.01 
CPB
 a
 1.31 (2.02) 0.82 (1.64) <0.01 
Tobacco use
 b
   <0.22 
  “Sometimes” 233 (21.8) 268 (23.7)  
  “Often” 15 (1.4) 24 (2.1)  
Alcohol use
 b
   <0.66 
  “Sometimes” 176 (16.5) 178 (15.8)  
  “Often” 13 (1.2) 10 (0.9)  
Drug use
 b
    
  “User” 35 (3.3) 25 (2.2) <0.12 
a
 Mean (SD), age 8-9, t-test for sex difference. 
b
 Frequency (%), age 13-14, chi-square test for sex difference. 
 
Table 7. Risk of substance use at age 13-14 (ORs, with 95% CIs) by ADHD symptoms and CPB.  
 Substance use at age 13-14 
 Tobacco  Alcohol  Illicit drug 
 “Sometimes” “Often”  “Sometimes” “Often”   
HI        
 Unadjusted  1.10 (1.03-1.18) 1.32 (1.13-1.56)  1.11 (1.03-1.20) 1.17 (0.94-1.46)  1.16 (0.98-1.37) 
 Fully adjusted  1.12 (1.03-1.22) 1.13 (0.91-1.41)  1.05 (0.96-1.15) 0.91 (0.66-1.27)  1.10 (0.90-1.35) 
IN        
 Unadjusted  1.00 (0.90-1.10) 1.38 (1.12-1.70)  1.15 (1.04-1.27) 1.36 (1.04-1.79)  1.20 (0.94-1.53) 
 Fully adjusted  0.88 (0.77-1.00) 1.04 (0.75-1.46)  1.01 (0.88-1.15) 1.14 (0.70-1.89)  0.94 (0.68-1.30) 
CPB        
 Unadjusted  1.09 (1.02-1.16) 1.31 (1.18-1.46)  1.15 (1.09-1.23) 1.29 (1.14-1.47)  1.16 (1.02-1.33) 
 Fully adjusted  1.08 (1.00-1.16) 1.24 (1.09-1.41)  1.12 (1.04-1.21) 1.28 (1.09-1.52)  1.14 (0.96-1.34) 
Note: The “never use” category of the substance use variables was used as a reference group in all the models. 
Unadjusted ORs were adjusted only for sex. Fully adjusted ORs were adjusted for sex, the other ADHD dimension, 
and CPB at the same age.  
 
Since our analyses showed that ADHD’s association with tobacco and alcohol use were 
specifically linked to the HI dimension, we conducted twin analyses to explore the 
extent to which these associations were influenced by genetic or environmental factors. 
To maximize the power, twin analyses were conducted using cross-sectional measuers 
of both HI and substance use at age 13–14. The phenotypic polychoric correlation 
between HI and tobacco use and between HI and alcohol use were 0.25 (95% CI, 0.15–
0.34) and 0.22 (95% CI, 0.11–0.32), respectively. The parameter estimates from the 
best-fitting model, which constrains the genetic, shared and non-shared environmental 
parameters to be the same for boys and girls, is presented in Table 8. HI showed a high 
heritability (h
2
=0.81), and tobacco use showed a moderate heritability (h
2
=0.60). A 
significant genetic correlation was observed (rg=0.30), and 82% of the phenotypic 
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correlation between HI and tobacco use was explained by genetic influence. Similar 
pattern of results were observed for HI and alcohol use. 
 
Table 8. Parameter estimates of genetic and environmental effects (95% CI) from bivariate correlated 
factor models. 
 h2 c2 e2 rg rc re G%
* 
HI and tobacco use         
HI 0.81 
(0.68-0.86) 
0.00  
(0.00-0.10) 
0.19 
(0.14-0.26) 
0.30 
(0.11-0.57) 
0.01 
(-1.00-1.00) 
0.31 
(-0.09-0.53) 
82% 
Tobacco use 0.60  
(0.40-0.83) 
0.28 
(0.07-0.47) 
0.11 
(0.07-0.17) 
    
HI and alcohol use        
HI 0.81  
(0.68-0.86) 
0.00 
(0.00-0.10) 
0.19 
(0.14-0.26) 
0.39 
(0.19-0.76) 
-0.00 
(-1.00-1.00) 
-0.16 
(-0.50-0.19) 
N/A 
Alcohol use 0.61 
(0.33-0.88) 
0.22 
(0.00-0.46) 
0.17 
(0.11-0.26) 
    
* G%, proportion of phenotypic correlation explained by shared genetic influence. 
 
5.4 STUDY IV 
Males with ADHD showed significantly higher rates of accidents than males without 
ADHD (Table 9); the unadjusted HR was 2.45. This association was attenuated but 
remained significant, after controlling for socio-demographic factors, previous 
psychiatric diagnosis, other psychotropic medications, and criminal convictions (HR = 
1.47). The results for females were similar (adjusted HR = 1.45). 
 
Table 9. Association between ADHD and serious transport accidents in Swedish adults. 
Gender ADHD 
Person-years 
at risk 
Number of 
accidents 
Crude association Adjusted association 
    HR 95% CI HR 95% CI 
Males ADHD 41,793 897 2.45 2.27-2.65 1.47 1.32-1.63 
 non-ADHD 415,662 3,217 1 - 1 - 
Females ADHD 27,399 330 2.10 1.86-2.38 1.45 1.24-1.71 
 non-ADHD 271,866 1,417 1 - 1 - 
 
To explore the association between ADHD medication and serious transport accidents, 
all subsequent analyses were based on ADHD patients. Comparing the accident rate 
during medication and non-medication periods in males showed that ADHD 
medication decreased the accident rate by 29% (HR= 0.71), as shown in Table 10. The 
association was not statistically significant in females (HR=0.92). Since patients 
receiving medication might be different from the non-medicated patients, a within-
individual analysis comparing the risk between medication and non-medication period 
is a more informative test of the association. For men, the stratified Cox Regression 
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showed that medication decreased the accident rate by 58% in males (HR=0.42, Table 
8). This illustrated that even within an individual ADHD medication was associated 
with a significant reduction of accidents, after controlling for all confounds that are 
constant during follow-up and measured time-varying covariates. Again, we did not 
observe a significant association among females. 
 
Table 10. Rate of serious transport accident during medication periods compared to non-medication 
periods among Swedish adults with ADHD. 
Gender Medication 
Person-years 
at risk 
Number of 
accidents 
Between-individual Within-individual 
    HR 95% CI HR 95% CI 
Males medicated 8,377 144 0.71 0.57-0.89 0.42 0.23-0.75 
 
non-
medicated 
33,416 753 1 - 1 - 
Females medicated 6,195 67 0.92 0.78-1.23 2.35 0.83-6.64 
 
non-
medicated 
21,204 263 1 - 1 - 
 
Our estimates of the PAF suggest that, under certain assumptions, 41% to 49% of the 
accidents in male patients with ADHD could have been avoided if they had been 
medicated during the entire follow-up.  
 
5.5 STUDY V 
We investigated long-term associations between stimulant ADHD medication and 
substance abuse by comparing patients on medication with those not on medication on 
January 1, 2006. Patients on medication did not have increased rates of substance abuse 
during follow-up; on the contrary, the rate of abuse during 2009 was lower for those on 
medication on January 1, 2006 (Table 11). After controlling for age, sex and 
medication in 2009, the substance abuse rate decreased by 48% (HR = 0.52, Model 1). 
The decrease in rate was 31% when we controlled for other potential confounders in 
Model 2 (HR=0.69). For each year an individual took stimulant ADHD medication 
before the follow-up there was a 13% (HR=0.87, 95% CI: 0.80-0.94) decrease in the 
rate of substance abuse registrations during 2009, after controlling for all confounders 
before 2006. Therefore, the results suggested no indication of increased risks of 
substance abuse among individuals prescribed stimulant ADHD medication. 
 
In addition to long-term effects, we also investigated short-term associations between 
stimulant ADHD medication and concomitant substance abuse in the cohort of 26,393 
men and 12,548 women with an ADHD diagnosis, who were alive in 2006. 
Concomitant substance abuse was less common during periods with stimulant ADHD 
medication according to the between-individual analyses (HR=0.57). Similar to Study 
IV, a within-individual analysis was performed by comparing the risk between 
medication and non-medication periods. The within-individual estimate of HR was 
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0.73 (95% CI: 0.68-0.77). Thus, even within individuals, stimulant ADHD medication 
reduced the concomitant substance abuse rate by about 27%. 
 
Table 11: Stimulant ADHD medication in 2006 and hazard ratio for substance abuse during 2009.  
 Model 1 Model 2 
 HR 95% CI HR 95% CI 
Stimulant ADHD medication 
in January 1, 2006 
 
0.52 0.42-0.66 0.69 0.57-0.84 
Duration of treatment with 
stimulant ADHD medication 
2006- 2008 (in years) 
0.80 0.73-0.88 0.87 0.80-0.94 
Model 1: Adjusted for sex, age and ADHD medication in 2009 as time-dependent covariates. 
Model 2: In addition to model 1, adjusted for socio-demographic factors (civil status, employment, study, living in 
metropolitan area, income), non-substance abuse psychiatric diagnoses, non-substance-related criminal convictions, 
and substance abuse at baseline. 
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6 DISCUSSION 
6.1 FINDINGS AND IMPLICATIONS 
The findings of this thesis indicate that ADHD is highly heritable from childhood to 
early adulthood. Young maternal age at childbearing is associated with increased risk 
for subsequent ADHD in offspring, but the association is probably best explained by 
genetic confounding. ADHD predicts transport accidents and substance abuse, and 
ADHD medications appear to be useful in reducing the rate of these adverse 
consequences of ADHD. 
 
6.1.1 Heritability of ADHD throughout development 
Study I found that the shared view of self- and informant-rated ADHD, measured using 
the AP scale, was highly heritable in childhood, adolescence, and early adulthood.  
 
To our knowledge, this study is the first to show that multi-informant ratings of 
ADHD-related phenotypes in adults are highly heritable, which is consistent with 
findings from clinical-based family studies that show a high familial loading on ADHD 
in adults [133]. One possible explanation is the use of multiple informants. In the basic 
twin model, the non-shared environmental (E) component captures the variance due to 
both unique environmental influences and measurement error. The multi-informant 
design, used in this study, enabled us to distinguish true unique environmental effects 
from variance explained by rater-specific measurement error. Our results suggest that 
heritability estimates for ADHD are stable during the transition from childhood into 
young adulthood and that the previous reports of low heritability for ADHD symptoms 
in adults are best explained by rater effects attributable to measurement error, rather 
than by developmental effects.  
 
The developmental design of this study allowed us not only to make the cross-sectional 
heritability estimates across different ages, but also to distinguish between stable and 
dynamic genetic factors during development. We found evidence of both stable and 
dynamic genetic influences over the course of the development from childhood into 
early adulthood. Consistent with the available literature [208-211], our results suggest 
that molecular genetic studies of ADHD symptoms in adults will identify genes that are 
shared with childhood ADHD, which represent developmentally stable genetic 
influences. Such studies will also identify genes that become active later in life that 
may involve processes that lead to the persistence or remission of the disorder as 
children with ADHD grow older. Taken together, our findings indicated that a multi-
informant measure of ADHD can identify a highly heritable phenotype and that 
different genetic risk factors account for the heritability at different stages of 
development. Therefore, the use of longitudinal samples with multi-informant measure 
may be able to refine phenotype with less heterogeneity, to be able to identify 
replicable genetic variants associated with ADHD. 
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A critical assumption for longitudinal studies is that the phenotype under study “looks” 
the same across development. The finding of dynamic genetic influences may partly 
reflect differences across time in the assessment of AP. In contrast to this alternative 
explanation, we observed similar heritability estimates with sensitivity analyses using 
(a) DSM-oriented ADHD scale from the empirically based assessment (CBCL, YSR, 
ABCL and ASR) [183,212], and (b) a reduced number of AP items that were same at 
all times and for all scales.  
 
6.1.2 Young maternal age and offspring ADHD 
Study II examined the association between maternal age at childbearing and offspring 
ADHD, and the results supported two main conclusions. First, maternal age at first 
birth (and not maternal age at the current birth) predicted offspring ADHD. Thus, all 
offspring born to a mother who began childbearing early were at increased risk of 
ADHD. It is particularly important for prevention purposes to be aware of that later-
born offspring of teenage mothers are also at increased risk of developing ADHD.  
 
Second, the association between MAFB and offspring ADHD was mainly explained by 
genetic confounding attributable to passive gene-environment correlations. That is, 
genetic factors transmitted from mothers to children contributed to both age at 
childbearing and ADHD in offspring. A similar result was found in a study on maternal 
age and cognitive test score [213]. In contrast, other studies have provided support for a 
causal mechanism underlying the association between MAFB and offspring disruptive 
behaviors and criminal convictions [139,140]. The conflicting results might suggest 
different etiologies for ADHD and other externalizing psychopathology. If MAFB is 
causally associated with offspring outcome, then it represents shared environmental 
influence within a nuclear family. Our results found little shared environmental 
influence on ADHD, which is consistent with a meta-analysis of twin studies [214] that 
reported that shared environmental influence accounted for 10%-19% of the variance 
within broad externalizing disorders, and the only exception was ADHD, which 
appeared to be largely genetic in origin. 
 
Teenage childbearing is internationally recognized as a public health issue with adverse 
consequences for both young mothers and their children [138]. Although young 
maternal age itself does not cause offspring ADHD, it is an important risk marker for 
all children born to young mothers. Our results suggest that public policy initiatives 
should strive not only to delay childbearing in the population, but to identify individual 
at-risk mothers and their children who may need support. Our findings are also likely to 
contribute to the understanding of the etiology of ADHD. What are usually believed to 
be environmental risk factors may also be markers of genetic predispositions. Our 
results highlights the importance of using genetically informative studies when trying 
to understand how early life circumstances affect child development. 
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6.1.3 ADHD and early-onset substance use 
Study III found that the hyperactivity-impulsivity symptom dimension of ADHD, but 
not inattention, independently predicted early-onset tobacco use, even after controlling 
for CPB. In line with previous research [95], our prospective findings suggest that 
hyperactivity-impulsivity and CPB make unique contributions to the risk of smoking 
initiation (“sometimes” use). These results are consistent with the hypothesis that the 
association between childhood behavior and substance use is not entirely attributable to 
the developmental tracking of antisocial behavior, but is part of a more general process 
of behavioral disinhibition [215]. In contrast to our findings, several previous studies 
have found an independent association between inattention and later substance use 
[96,149,150], which supported the self-medication hypothesis. However, these studies 
focused on substance use during mid-adolescence and early-adulthood, whereas we 
studied early-onset substance use. This difference is important since prior research 
suggests differences in etiology between substance use in mid-adolescence/early 
adulthood and the less common early-onset type [216,217]. In addition, developmental 
research suggests different substance use trajectories, including an early-onset group 
and a late-onset group, which vary in severity and persistence [218-220]. 
 
The twin analyses showed that the association between hyperactivity-impulsivity and 
early-onset substance use were mainly influenced by genetic factors. Our results are 
consistent with accumulating evidence of a common behavioral and neurobiological 
bases for ADHD and smoking [221]. Unfortunately, because of the limited sample size 
and the use of categorical measures, we did not have sufficient power to simultaneously 
include hyperactivity-impulsivity and CPB in a multivariate design that could clarify 
whether the shared genetic liability with substance use is specific to hyperactivity-
impulsivity, or common to other behavior problems. 
 
6.1.4 ADHD, transport accidents, and the effect of medication 
Study IV found that ADHD patients had increased risk for serious transport accidents 
and that ADHD medication was associated with reduced rates of accidents in males 
patients, even when using within-individual analyses. 
 
The study found that men and women with ADHD had 42% - 47% increased rate of 
serious transport accidents compared to individuals without ADHD. The magnitude of 
the association was similar to results from a population-based, case-control study in 
North American [160]. Studies have suggested that visual inattentiveness and 
impulsiveness are the largest contributions to the risk of transport accidents in ADHD 
patients [108]. Medications that alleviate ADHD symptoms might be expected to 
translate into safer driving behavior and, therefore, to reduce the risk of accidents [222]. 
Consistent with experimental and clinical studies on the effect of medication on driving 
[107,159,161,223], our results clearly indicate that ADHD medication was associated 
with reduced rates of serious transport accidents. 
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This is the first population-based study of ADHD medication and serious transport 
accidents. Population-based register data have several strengths compared to clinical 
studies. The sample size is substantial and representative for the population, therefore 
avoiding referral bias, selective participation, and other threats to validity and 
generalizability. Nevertheless, observational studies are always susceptible to selection 
effects [125]. A major threat in studies of medications is that some patients might 
receive medication because they are different (usually more symptoms or with 
comorbid conditions). Unlike RCTs, which randomly assign participants to treatment 
conditions, observational studies like ours cannot control for all possible confounders 
that select individuals to treatment. Our main attempt to control for this was to use 
within-individual analyses, which adjusts for all potential confounders that are constant 
during the follow-up (genetic predisposition and early environment). However, 
unmeasured confounders and mediators that vary during follow-up (engagement with 
services that provide prescriptions, cyclic nature of the disorder itself, substance use, or 
crime) cannot be completely ruled out by this research design. Although all of the 
sensitivity analyses were consistent with a causal hypothesis, they were only 
suggestive. Thus, future RCTs or observational studies that include information about 
medication dosage are obviously needed. 
 
Our estimates of the PAF suggested that, under certain assumptions, 41% to 49% of the 
accidents in male patients with ADHD could have been avoided if they had been 
medicated during the entire follow-up period. It is important to note, however, that the 
PAF estimates will be lower in countries with higher prescription rates than Sweden 
[128,129] and that the beneficial effects of ADHD medication needs to be weighed 
against potential adverse effect, including side effects and over-prescription. 
 
Transport accidents are a major public health problem. Our findings call attention to a 
prevalent, preventable and costly cause of mortality and morbidity. The association 
between ADHD and serious transport accidents does not, by itself, justify withholding 
a driver’s license; nevertheless our findings indicate that a large number of injuries and 
death from traffic accidents associated with ADHD occurred during periods when 
patients were off medication. Clinicians should consider telling patients about the 
increased risk for transport accidents associated with ADHD, as well as, the possible 
benefits of ADHD medication. This would provide opportunities not only to reduce 
morbidity and mortality among ADHD patients, but also to contribute to public safety 
in transport. 
 
6.1.5 ADHD medication and risk of substance abuse 
ADHD medication has been shown to have advantageous short-term effects on ADHD 
symptoms, as well as reducing concomitant criminality [122] and transport accidents 
(Study IV). Even though the short-term effects can be beneficial, there has been a 
persistent concern that treatment with stimulant medication could lead to long-term 
development of substance abuse. In Study V we followed almost 40,000 individuals 
with ADHD over 4 years, and found no indication of increased substance abuse, which 
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is consistent with a recent meta-analysis [163]. Rather, the results indicated there was a 
decrease in substance abuse for up to four years after taking medications, and that 
patients who took ADHD medications for longer durations had lower rates of substance 
abuse. Critics of ADHD medication have been specifically concerned about the 
substance abuse risk for youth [172,224,225], but we found no indication of long-term 
increase in substance abuse in this group. 
 
One possible mechanism of the long-term association between ADHD medication and 
substance abuse would be that ADHD medication leads to less exposure to substances 
and, thus, less chance of developing dependence or addiction. An alternative 
explanation to the results is reverse causation. That is, that substance behavior before 
2006 is correlated with substance abuse in 2009 and that the earlier substance abuse 
(which may have been subclinical) decreased the likelihood of being prescribed ADHD 
medication. However, several sensitivity analyses indicated that the results were not 
likely to be explained by reverse causation. 
 
Again, it should be noted that observational studies are susceptible to selection effects. 
In our analyses of short-term associations, we addressed this problem using within-
individual analyses and found similar reduction in substance abuse rates, but it was not 
possible to do this for long-term associations. Ideally, these results should be replicated 
in RCTs, but a trial of long-term effects of ADHD medication is unlikely to be feasible 
because of practical and ethical reasons.  
 
In summary, although we argue that concerns over long-term risks for substance abuse 
following ADHD medication probably have been overstated, the decision to prescribe 
stimulant ADHD treatment should, as in all clinical practice, take into account 
individuals factors and potential adverse effects. Future studies are needed to evaluate 
the long-term effect of ADHD medication on other important medical risks, for 
example, cardiovascular risk [226] and suicide [227]. When considering ADHD 
medication, it is also important to acknowledge the risk for over-prescription; clinicians 
should remain alert to the problem of stimulant misuse and diversion [228]. 
 
6.2 METHODOLGICAL CONSIDERATIONS 
6.2.1 Measurement issues 
6.2.1.1 Assessment of ADHD 
The main phenotype in this thesis is ADHD, and it has been used as exposure, 
outcome, and definition of cohort in different studies. 
 
In Study I and III, we used questionnaire-based ADHD symptoms. In Study I, we used 
the parent- and self-ratings of AP scale to measure ADHD symptoms. In Study III, we 
used parent-ratings of DSM-based ADHD symptoms. Both measures have been used in 
many previous epidemiological studies of ADHD, representing good psychometric 
properties, as described in the study sample section (3.1.3). However, they have some 
limitations that need to be mentioned. First, the AP scale was not specifically designed 
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to identify the two symptom domains of ADHD (inattention and hyperactivity-
impulsivity), and this may have limited its ability to detect subtype-specific dominant 
genetic effects. Also, some of the items in the AP scale are not ADHD specific (e.g., 
acts young, daydreams). Second, although the parents were asked to rate their 
children’s behavioral problems exhibited in the past six months, it is possible that 
ratings in early adulthood (age 19-20 years) may be influenced by the offspring’s 
behavior at earlier ages. Third, the measure of ADHD in Study III has not been 
formally validated, and because of the definitional changes in the DSM during the 
follow-up period, our measurements did not cover all of the HI and IN symptoms 
included in the DSM-IV. However, the instrument has been previously used in several 
epidemiological studies that replicated several well-established findings in the ADHD 
literature [32,134,175,176]. In addition, the measure of ADHD in Study III relied on 
only parent reports, which might inflate the twin correlations. However, the heritability 
estimate from Study III was similar to that from Study I, which used multi-informants. 
Finally, because symptoms of ADHD were measured using questionnaires in a 
population-based twin sample, it is not certain that the results are generalizable to 
clinical settings. 
 
In Study II, we used register-based ADHD diagnosis as the outcome. To improve 
sensitivity, we used a conjunctive definition of clinical ADHD, including individuals 
either received ADHD diagnoses according to the NPR or treated with ADHD 
mediation according to the PDR. In general, Swedish psychiatrists are rather 
conservative with respect to diagnosis and medication, and they tend to complete 
detailed clinical assessment. Thus, the register-based ADHD diagnosis should represent 
high specify. This is also supported by our own validity check on the register-based 
ADHD diagnoses using a young cohort of twins with psychiatric symptom data [229]. 
Nevertheless, future studies should formally validate the diagnosis of ADHD using 
Swedish registers. 
 
In Study IV and V, we used register-based ADHD diagnoses to define the patient 
cohort, which included patients with at least one diagnosis of ADHD in the NPR since 
2001. Historically, some counties have been less consistent in reporting outpatient data 
to the NPR. To address this potential selection bias, we also analyzed cohorts of 
individuals that received at least one prescription for ADHD medication during follow-
up (identified from the PDR, which has complete coverage), but not necessarily had a 
registered ADHD diagnosis, and both analyses yielded comparable results. 
 
With respect to its associations with genetic and environmental risk factors, ADHD 
appears to behave like a dimensional measure rather than as a qualitative discrete 
category [13]. Although a clinical diagnosis of ADHD is essential to identify 
individuals who need care and treatment, research, ideally, should use both clinical 
diagnosis (case/no-case) and measures of symptom dimensions. Dimensional 
approaches are valuable to use because they are more sensitive for studying risk factors 
and adverse consequences related to ADHD, whereas clinical diagnosis is valuable to 
use in order to be able to generalize the results to clinical populations. 
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6.2.1.2 Measurement of ADHD medication 
In Study IV and V, we measured ADHD medication using dispensed prescriptions, and 
our study might be affected by poor compliance with medication adherence. This is 
similar to the situation in RCTs and our effect estimate can be compared to an intention 
to treat analysis. We used a 6-months cutoff between prescriptions to define “off 
medication” based on previous research. To explore the potential influence of exposure 
misclassification, we re-analyzed the data with a 3-months cutoff and found similar 
result (Study IV). If some individuals did not take medication as prescribed, this would 
reduce the effect estimates; hence, our findings are probably conservative estimates of 
the actual effects of medication on transport accidents. 
 
6.2.1.3 Measurement of other outcomes 
There are measurement issues regarding other outcomes that also need to be discussed. 
Substance use in Study III was measured only by self-reports, which could be 
considered a limitation of the study [230]. Although most epidemiological research on 
substance use disorders rely on self-reports, family or peer reports may have 
strengthened the results. Nevertheless, self-reports may be the preferred method to 
measure substance use among adolescents in community settings [231], because 
adolescents may be more likely to reveal private information in an anonymous 
questionnaire than to their parents. 
 
In Study IV we used emergency hospital visits or deaths from transport accidents as our 
primary outcome, which are fairly serious outcomes. Similarly, in Study V we used 
medical and legal records of substance-related hospitalizations, deaths and convictions 
to measure substance abuse. While using information from registers has the important 
advantage of precluding recall bias, registers included mainly cases of serious 
outcomes. Future research needs to explore whether our findings generalize to less 
severe outcomes. 
 
6.2.2 Causal inference from observational data 
"Correlation is not causation" is a mantra in epidemiology and statistics. Although 
many factors have been identified that are correlated with ADHD, their causal 
connection to ADHD is not well established. A correlation between two variables (e.g., 
exposure and outcome) is often found in observational studies, which may imply that 
the exposure has a causal effect on the outcome. However, the observed correlation 
could have alternative explanations. The use of longitudinal designs and representative 
samples can eliminate some alternative explanations, such as selection bias or reverse 
causation. The following discussion will focus on controlling bias from confounding 
that is the most common threat to making causal interpretations from observational 
studies. Causal effects are defined according to the modern "counterfactual model", and 
all causal effects refer to ‘average causal effects’ in a population [232]. 
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Experimental designs offer the most plausibly unbiased estimates of causal effect. In 
RCT’s, individuals are randomly assigned to different treatments so that the different 
treatment groups should not differ significantly from each other on their observed or 
unobserved characteristics, at baseline, assuming an adequate sample size. Therefore, 
any observed differences in outcomes can be explained only by the differences in the 
treatments. However, RCTs are often not feasible because of cost or ethical reasons. 
 
In observational studies, many efforts are taken to control or reduce biases produced by 
confounding. From a research design perspective, matching participants on potential 
confounding variables provides a straightforward strategy, in which case-control groups 
or exposed-unexposed groups are created based on matching variables. From an 
analytic perspective, stratification and multivariate regression analyses are the most 
commonly used methods. Each approach has its advantages and disadvantages. 
However, these approaches have the common limitation that they can control for only 
those confounders that are measured, and only to the extent that they are measured 
correctly. 
 
Quasi-experimental designs offer an attractive alternative. Family-based, quasi-
experimental designs can provide highly informative tests of causal hypotheses by 
substantially reducing genetic and environmental confounding (see section 4.1.2). By 
studying associations within sets of family members (e.g., siblings), the analysis 
automatically controls for unmeasured genetic and environmental factors shared by 
siblings, without having to model or even measure these factors (Study II). However, 
influence of non-shared confounders and measurement errors cannot be ruled out in 
such designs, interpretation of the results should be made with caution [199]. 
 
Time-series within-individual analysis represents another powerful quasi-experimental 
design. Within-individual estimates automatically adjust for confounding by all 
unmeasured covariates that are constant within each individual during the follow-up 
period (e.g. genetic predisposition and early environments) (Study IV and V). It should 
be noticed that within-individual analysis cannot adjust unmeasured confounders that 
varied during follow-up (e.g., engagement with health care services, cyclic nature of 
diseases).  
 
In addition to reducing potential confounding, one can use negative control analyses to 
estimate the magnitude of influence of confounding. Negative control analysis 
examines the association between exposure and outcome, using (a) an outcome that is 
presumed not to be causally associated with the exposure (negative outcome control), 
or (b) an exposure that is presumed not to be causally associated with the outcome 
(negative exposure control). If the negative control analysis finds associations similar to 
the initial analysis, then the initial analysis is likely to be biased by confounds. On the 
other hand, if one finds an association in the initial analyses, but no association in 
negative controls, the causal interpretation is strengthened. In Study IV we used 
selective serotonin reuptake inhibitor as a negative control, when studying the 
association between ADHD medication and transport accidents. This analysis enabled 
 42 
us to compare the general effects of being prescribed medication (which might be 
influenced by time-varying confounding, such as access to medical service) with the 
specific effects of ADHD medication. 
 
Mendelian randomization is another recent development in causal inference, which 
relies on the random assignment of each individual’s genotype, and can be considered 
as analogous to RCTs [233]. While none of designs can completely control for all 
potential confounding, well-designed observational studies can substantially reduce the 
number of alternative explanations of apparent causal effects. Moreover, confidence in 
a finding is strengthened when different designs with different flaws support the same 
conclusion. 
 
6.2.3 Twin methodological issues 
The findings of Study I and III should be considered within the context of several basic 
assumptions underlying twin methodology. 
 
6.2.3.1 Equal environment assumption 
One of the fundamental assumptions in twin methodology is the equal environment, 
which assumes that environmentally caused similarity is roughly the same for both 
types of twins (i.e., MZ and DZ) reared in the same family. The assumption is violated 
if MZ twins are treated more similarly than DZ twins, which in turn would inflate the 
estimate of genetic effect. Although the equal environment assumption has been 
debated, various checks, such as incorporating environmental measures in twin studies 
and analyzing the effects of mistaken zygosity, suggest that the assumption is generally 
valid [234]. Specifically, studies have found the assumption is valid for ADHD and 
other psychiatric disorders [235,236]. 
 
6.2.3.2 Assortative mating 
The basic twin model assumes random mating in the parent generation. Assortative 
mating occurs if individuals with similar phenotypes mate with one another more 
frequently than individuals with dissimilar phenotypes. If the phenotypic similarity is 
due to genetic similarity, the offspring will be genetically more similar. Assortative 
mating increases similarity in DZ twins, thereby underestimating the genetic influence 
and overestimating the shared environmental influence. Consistent with previous 
research [214], we found no evidence of shared environmental influence on ADHD, 
suggesting that the potential effect of assortative mating is minimal. 
 
6.2.3.3 Non-additive genetic effect 
The basic twin model often focuses on additive genetic effects, assuming that the 
effects of alleles at a locus and across loci are independent and, therefore, additive. 
However, the effect of alleles can also interact with other alleles at the same locus 
(dominance) or at other loci (epistasis) [234]. Non-additive genetic effects may be 
present if DZ correlations are less than half of MZ correlations. If non-additive genetic 
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effects are present but not modeled, this variance will be estimated as additive genetic 
variance. Study I found evidence that at least part of the heritability of AP is due to 
non-additive genetic effects. 
 
6.2.3.4 Gene-environment interaction/correlation 
The basic twin model assumes that influences of genes and environments on a 
phenotype are independent. In addition to the direct effects of genes and environments, 
there may be an interplay between them through gene-environment interactions and 
correlations [147]. Gene-environment interactions refer to the possibility that 
individuals of different genotypes may respond differently to environments. 
Susceptibility gene variants for ADHD have been identified with emerging evidence of 
gene-environment interaction [237]. Gene-environment correlations refer to the 
possibility that individuals with different genotypes are selectively exposed to different 
environments. The finding in Study II provided an example of gene-environment 
correlation; that is, a putative environmental risk factor (i.e. young maternal age) was 
influenced by genetic factors, which were transmitted from parents to their offspring 
and accounted for the risk of ADHD. 
 
6.2.3.5 Generalizability from twins to singletons 
Twins may differ from singletons with respects to lifestyle characteristics and 
psychological development [238,239]. Although numerous studies suggest that the 
results of twin studies can be generalized to singleton populations [240,241], the nature 
of the sample has to be taken into account when interpreting results from twin studies. 
In any case, two previous reports have shown that the mean levels of emotional and 
behavior problems (measured by CBCL) in the current TCHAD sample is similar to 
that found in other Swedish samples [242,243]. 
 
6.3 GENERLIZABILITY 
All the studies in this thesis used data from the Swedish population, and the rates of 
ADHD and ADHD medication use, and other variables studied in this thesis (e.g., 
teenage childbirth, traffic fatality and disability, use of illegal drugs) are lower in 
Sweden compared to other developed counties (e.g., the United State) 
[16,129,138,157,244,245]. However, the magnitude of the heritability of ADHD and 
the associations of other study variables with ADHD were generally similar to those 
reported in studies from other countries. Nevertheless, we cannot claim that our 
findings are the same as those from other cultures/countries and, thus, generalizations 
from the current studies should be made with caution. 
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7 CONCLUSIONS 
 
I. ADHD is highly heritable in childhood, adolescence, and early adulthood, 
suggesting that the previous reports of low heritability for ADHD in adults are 
best explained by rater effects. Both stable and dynamic genetic influences are 
present over the course of the development. 
 
II. Maternal age at first birth (and not maternal age at the current birth) predicted 
offspring ADHD. Thus, all offspring born to teenage mothers were at increased 
risk of ADHD. This association is mainly explained by genetic confounding. 
That is, genetic factors transmitted from mothers to children contribute to both 
mother’s age at childbearing and ADHD in offspring. 
 
III. Hyperactivity-impulsivity symptoms, but not inattention, independently predict 
early-onset tobacco use, even after controlling for conduct problems, and this 
association was mainly explained by shared genetic factors. 
 
IV. ADHD is associated with an increased risk of serious transport accidents, and 
this risk seems to be reduced by ADHD medication, at least among male 
ADHD patients. These findings indicate the need for increased awareness of the 
association between serious transport accidents and ADHD medication among 
clinicians and patients. 
 
V. There is no indication of increased risks of substance abuse among individuals 
prescribed stimulant ADHD medications, and the results suggest there may be a 
long-term protective effect of such medications on substance abuse. Although 
stimulant ADHD medications do not seem to increase the risk for substance 
abuse, clinicians should remain alert to the potential problem of stimulant 
misuse and diversion in ADHD patients. 
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8 FUTURE PERSPECTIVES 
8.1 TWIN STUDIES IN THE OMICS ERA 
The classical twin model can provide insight into the etiology of diseases, and it has 
revealed the importance of genetic influence on many diseases, including ADHD. 
During the last years, GWAS has provided a revolutionary approach to search for 
genetic variants susceptible to disease. In the current era of molecular genetics, the use 
of classic twin studies combined with novel technologies should continue to provide 
valuable insights to the understanding of complex diseases [246]. 
 
There is an ongoing discussion about “missing heritability”, which largely stems from 
the disparity between the heritability estimates from twin studies and the proportion of 
variance explained from GWAS [247]. One argument is that the heritability from twin 
studies may be overestimated. A recent approach has been proposed to estimate 
heritability directly from DNA similarity (genome-wide identity-by-descent sharing) 
[248]. The estimate of heritability of height based on genome data was highly 
consistent with results from classical twin studies, which provided strong support for 
the heritability estimate from twin studies. The validity of heritability estimates from 
twin studies is further supported by the finding that common SNPs explain a large 
proportion of the heritability of height, schizophrenia and bipolar disorder [249,250]. 
Thus, most of the heritability of complex traits is not missing, although it has not been 
detected yet. 
 
The few GWASs on ADHD performed so far have failed to identify any common 
genetic variant that reaches the genome-wide significance level. One explanation could 
be due to the heterogeneous nature of the disorder, and twin study can provide 
predictions and refined phenotypes for molecular genetic studies [251]. Longitudinal 
twin model can identify stable genetic influences through the development of a disease, 
as well as age-specific genetic influences. Similarly, multivariate twin model can 
identify shared genetic influences across several comorbid disorders, as well as 
disorder-specific genetic influences.  
 
Twin studies can also help to identify endophenotypes of behavioral disorder. 
Endophenotypes are considered as intermediate phenotypes in the pathway between 
genes and disorder, with a simpler etiology that the complex, often heterogeneous 
disorder itself [252]. Neuropsychological measures, structural and functional neuro-
imaging and electrophysiological paradigms have been suggested as potential 
endophenotypes for ADHD, which show correlations with ADHD and evidence of 
heritability [253]. Twin studies can be an important tool to identify the genetic overlap 
between these constructs and ADHD [254]. 
 
In addition to providing estimates of genetic and environmental influences, the 
comparison of discordant twins (especially discordant MZ twins, also known as co-
twin control method) is a powerful tool compared to the traditional case-control study. 
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The discordant twin design has long been used to test the causality of putative 
environmental risk. It also offers a unique opportunity to study biological processes 
(e.g., DNA methylation, gene expression) against an equivalent genetic background 
[247].  
 
Twin registries worldwide have collected longitudinal data on thousands of twins, 
providing valuable resources for studying complex disorders. Pooling information from 
available twin registries will further increase the analytical power of studies and 
provide a unique opportunity for large-scale studies on complex disorders. 
 
8.2 BEYOND GENETIC AND ENVIRONMETNAL RISK FACTORS 
Although many environmental factors have been proposed as risk factors for ADHD, 
for the most part their causal connection to ADHD remains unclear. It is also unclear 
whether these factors influence the risk of ADHD independently, or interactively. 
Moreover, if they do interact, it is unknown to what extent they interact with each 
other, or with genetic factors. Gene-environment interactions are likely to be a common 
and important source of variation in complex behavioral traits. Genetic predisposition 
can influences vulnerability to environmental stress, and environmental exposure can 
also influence the expression of susceptible genes. Many studies have reported 
candidate gene by environment interaction in the development of ADHD [255,256]. 
Twin studies can provide evidence of gene-environment interaction by showing how 
genetic influences on a trait are changed by environmental moderators [257], and can 
provide targets for future genome-wide searches for gene-environment interactions. 
Gene-environment interactions are also an important potential explanation for the 
“missing heritability” [258]. Increasing knowledge of the genetic and environment 
interplay on ADHD could lead to a better understanding of the biological mechanisms 
of ADHD. 
 
We know that ADHD is associated with a wide range of adverse outcomes, but little is 
known about to what extent ADHD predicts these outcomes independently of other 
factors, and how ADHD and other factors jointly predict these outcomes. For example, 
ADHD patients with a particular environmental exposure may have a high risk for 
occupational difficulties, but no increased risk for driving problems. Patients with 
another environmental exposure may have a high risk for substance abuse. Because 
ADHD typically starts early in childhood, a predictive model of adverse outcomes is 
essential prevention and intervention. Therefore, future research is needed to explore 
how various factors (including ADHD) predict the risk of different adverse outcomes, 
and to identify high risk groups for prevention and intervention. By alerting parents of 
adverse outcomes, and routinely screening for these conditions, these adverse outcomes 
could be prevented, or treated at an early stage if emerged. The same reasoning applies 
to prediction of persistence versus remission of ADHD in adults. In view of the 
increasing number of ADHD diagnoses, such advancements can have a substantial 
impact on health economics globally.  
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